Introduction {#s1}
============

The Integrated Stress Response (ISR) is a eukaryotic cellular stress response, aiming to restore cellular homeostasis upon different types of extrinsic or intrinsic stresses. The ISR can be stimulated by a range of physiological or pathological changes ([@bib10]; [@bib18]; [@bib31]; [@bib90]; [@bib112]), including hypoxia, amino acid deprivation, glucose/nutrition deprivation, viral infection ([@bib18]; [@bib31]; [@bib112]; [@bib21]; [@bib91]; [@bib120]) and intrinsic endoplasmic reticulum (ER) stress ([@bib29]), which is caused by the accumulation of unfolded or misfolded proteins within ER. Furthermore, in the context of cancer biology, oncogene activation can also trigger the ISR ([@bib17]; [@bib32]). Although the ISR is primarily a pro-survival homeostatic program, aiming to optimize the adaptive cellular response to stress, exposure to severe stress, either in intensity or duration, will overwhelm the capacity of this adaptive response and drive signaling toward cell death.

The key early controlling step in the ISR is the phosphorylation of eukaryotic translation initiation factor 2 alpha (eIF2α) by one of four members of eIF2α kinase family: protein kinase R (PKR), PKR-like endoplasmic reticulum kinase (PERK), general control nonderepressible 2 (GCN2), and Heme-regulated eIF2α kinase (HRI) ([@bib18]; [@bib21]; [@bib29]; [@bib26]). These kinases phosphorylate serine 51 in eIF2α, promoting the formation of a p-eIF2α and eIF2B complex, consequently inhibiting the guanine nucleotide exchange activity of eIF2B ([@bib103]). Inactivation of the eIF2 complex leads to a shutdown of global protein synthesis but also the induction of preferential translation of transcripts notably the mRNAs of transcription factors, Activating Transcription Factor 4 (ATF4) and C/EBP homologous protein (CHOP, encoded by *Ddit3*), and other factors with both pro-survival and pro-death functions which aid cell adaption and recovery ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}) ([@bib28]). eIF2α phosphorylation is transient and can be reversed by PPP1R15A (GADD34) or CReP1, the regulatory subunit of eIF2α phosphatases, acting in a negative feedback loop that allows protein synthesis to restart ([@bib30]; [@bib75]). When the stress is intense or prolonged, cells fail to adapt, and apoptosis is triggered. It is likely that the duration and level of eIF2α phosphorylation, as well as ATF4 regulation, determine the balance between cell survival and cell death.

There are more than 400 human genetic skeletal disorders caused by disrupted cartilage and bone development and growth, commonly resulting in dwarfism and skeletal deformities ([@bib22]). Many of these disorders are caused by mutations in genes for extracellular matrix (ECM) proteins ([@bib22]; [@bib7]; [@bib9]; [@bib111]), and some mutations cause inappropriate folding, processing or export, leading to retention in the ER, affecting the secretory and stress response pathways ([@bib113]; [@bib107]; [@bib106]; [@bib85]; [@bib83]; [@bib33]; [@bib12]; [@bib8]; [@bib2]). Accumulation of misfolded proteins in the ER can overwhelm the protein quality control mechanism, causing proteotoxicity, cell cycle arrest and cell death. Cells activate the unfolded protein response (UPR), which mediates cell survival by slowing protein translation, promoting proteostasis via the proteasome and activating transcription factors that upregulate the production of protein chaperones (reviewed in \[[@bib40]; [@bib39]\]). The UPR employs three arms of sensors in the ER to mediate cell adaptation and survival under ER stress: the key component of the ISR, PERK, inositol-regulated enzyme 1α (IRE1α), and the activating transcription factor 6 (ATF6) family ([@bib40]; [@bib39]; [@bib109]). Upon ER stress, the PERK-p-eIF2α signaling modulates the cell adaptation via translational control. ATF6 family factors move from the ER to the Golgi, are processed by S1 and S2 proteases, and translocate to the nucleus to activate ER quality control genes such as *Hspa5* (encodes BiP) and *Xbp1* (X-box binding protein 1). IRE1α has kinase and endoribonuclease (RNase) activities. It catalyzes the splicing of *Xbp1* mRNA, generating the UPR transcription factor XBP1^S^ that upregulates genes encoding chaperones and proteins involved in ER-associated protein degradation (ERAD).

Human metaphyseal chondrodysplasia type Schmid (MCDS; MIM156500) is an autosomal dominant disorder caused by heterozygous mutations in the NC1 domain of type X collagen, encoded by *COL10A1* in hypertrophic chondrocytes (HC) ([@bib111]; [@bib113]; [@bib68]). In an MCDS transgenic mouse model (13del), carrying a 13 bp deletion in *Col10a1* equivalent to the human mutation, misfolded mutant collagen X induces ER stress suggesting the primary role of ER stress in MCDS pathogenesis ([@bib107]). Although the chondrocytes survive, their differentiation is reversed by an unknown mechanism to a more juvenile state characterized by the re-expression of prehypertrophic chondrocyte markers (*Ppr*, *Sox9* and *Col2a1*), disrupting endochondral ossification, and skeletal dysplasia ensues. The causative role of ER stress in MCDS is further supported by studies showing that expression of an exogenous misfolded protein in HCs can induce an MCDS-like phenotype ([@bib89]).

It is noteworthy that the skeletal defects caused by mutations that induce stress or inactivate critical transducers of the stress response in humans ([@bib45]) and mouse models ([@bib107]; [@bib12]; [@bib39]; [@bib89]; [@bib45]; [@bib76]; [@bib13]; [@bib11]) strongly implicate components of ER stress-induced UPR pathways involved in chondrocyte and osteoblast differentiation ([@bib106]; [@bib39]). Expression of misfolded cartilage oligomeric matrix protein (COMP) in proliferating and hypertrophic chondrocytes results in chondrocyte disorganization and causes Pseudoachondroplasia (PSACH), suggesting triggering the UPR may underlie many chondrodysplasias where mutations cause accumulation of misfolded proteins ([@bib85]; [@bib82]). Another example that links ER stress signaling to chondrocyte differentiation is illustrated by studies on BBF2H7, an ER stress transducer. *Bbf2h7* null mutants show severe chondrocyte abnormality due to proliferation and differentiation defects, indicating its essential role for chondrogenesis ([@bib92]; [@bib93]). Furthermore, BBF2H7 has been shown to suppress chondrocyte hypertrophy by direct regulation of IHH signaling and the IHH-PTHrP pathway ([@bib93]).

Pharmacological stimulation of intracellular proteolysis of mutant collagen X in another MCDS mouse model reduces the level of ER stress, partially ameliorating the dwarfism phenotype ([@bib72]). However, the rescue of the chondrocyte differentiation defect, expansion of the hypertrophic zone and bone growth was incomplete, suggesting stimulating degradation of misfolded protein alone is not sufficient to address the impact of the ER stress on aberrant cell differentiation.

The relative contribution of the arms of the UPR and its constituent components to the pathology and a molecular understanding of the consequences of activation of ER stress on cell fate and differentiation *in vivo* is lacking. Here by studying MCDS in a mouse model, we sought to clarify the mechanism(s) by which the UPR/ISR causes aberrant differentiation defects which may provide the basis for the development of novel therapeutic target(s) for treating this disorder, or other ER stress-related skeletal disorders. We reveal by genetic, biochemical and *in vivo* functional approaches in mouse models, ISR-mediated preferential translation of ATF4 directly activates inappropriate expression of the key transcription factor SOX9. This ectopic SOX9 expression in HCs reverts chondrocyte differentiation, thereby causing MCDS. By targeting the ISR early, at the level of p-eIF2α induction of ATF4, we ameliorate the pathology, thereby providing a rationale pharmacological strategy for treating MCDS and other skeletal disorders caused by activation of the ISR.

Results {#s2}
=======

The ER stress-induced UPR disrupts global transcriptome patterns in the chondrodysplastic growth plate {#s2-1}
------------------------------------------------------------------------------------------------------

The mammalian growth plate comprises four major sub-populations of chondrocytes: resting, proliferating (PC), prehypertrophic (pHC) and hypertrophic chondrocytes (HC). These chondrocytes have distinct morphologies and gene expression profiles governed by a precisely tuned gene regulatory network ([@bib38]). To investigate the effect of ER stress on the transcriptome of HCs, the proximal tibial growth plates from 10-day-old WT and 13del mice were fractionated into sub-populations representing proliferating (PZ), prehypertrophic (pHZ) and hypertrophic chondrocytes (HZ) ([Figure 1A](#fig1){ref-type="fig"}; [Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}). The wild-type HZ was fractionated into upper and lower zones (UHZ and LHZ) to capture early onset and late phases of hypertrophy. The *13del* HZ was fractionated into three zones: upper (UHZ) corresponding to the early phase of UPR activation, middle (MHZ) where HC adaptation would be initiated, and lower (LHZ) where HC should fully adapt.

![PERK signaling pathway, activated by ER stress, plays an etiological role in MCDS *13del* mice.\
(**A**) Schematic diagram of the rationale for fractionating the WT and 13del p10 growth plates into different chondrocyte populations. (**B**) Clustering analysis of differentially expressed genes in chondrocyte subpopulations in p10 WT and 13del proximal tibial growth plates. Expression levels were normalized from −0.5 (blue) to 0.5 (yellow). Four major clusters were identified. (**C**) The average expression levels (Log~2~ scale) of the genes in different clusters revealed significant expression pattern changes in 13del mice. (**D--E**) Genes in different clusters were functionally categorized using DAVID web tools. The enriched biological processes (**D**) and enriched pathways (**E**) were sequentially shown for Cluster I, II, III and IV. The values on the X-axis represented the Log~10~ (*p*-value^−1^). Each category with p-value \<0.05 was considered as significantly enriched. (**F**) Enriched motifs on Cluster I genes were identified, using sequences of the promoter region (±2 kb from the TSS) for these genes. Motifs matched to the TFs in the UPR were shown.](elife-37673-fig1){#fig1}

We used *k*-means clustering (see Materials and methods) to categorize the gene expression patterns across different zones in wild-type and 13del growth plates into four clusters ([Supplementary file 1](#supp1){ref-type="supplementary-material"}). Genes (453) in Cluster I increased expression from PHZ to lower HZ specifically in 13del HC ([Figure 1B and C](#fig1){ref-type="fig"}). Ontological analyses show these differentially expressed genes are mainly involved in protein processing in the ER and the UPR ([Figure 1D and E](#fig1){ref-type="fig"}, [Supplementary file 2](#supp2){ref-type="supplementary-material"} and [3](#supp3){ref-type="supplementary-material"}). Genes in Clusters II (659) and III (314) showed highest expression in wild-type PZ and pHZ followed by progressive downregulation from pHZ to LHZ but were upregulated in 13del LHZ, reflecting UPR-induced changes in HC differentiation ([Figure 1B and C](#fig1){ref-type="fig"}). These genes included *Sox9, Ppr*, and *Ihh,* consistent with our previous report of re-expression of pre-hypertrophic markers ([@bib107]). Cluster IV genes (680) showed increasing expression from pHZ to LHZ in wild-type and can be defined as 'hypertrophy characteristic' genes. Consistent with a change in the HC de-differentiation state in 13del, these genes were down-regulated in 13del LHZ. The concomitant down-regulation of Cluster I stress response genes in 13del LHZ is consistent with the alleviation of the stress in the reprogrammed cells and an adapted state.

We further compared our microarray dataset with the published data ([@bib12]) from another 2 MCDS mouse models, expressing a Col10a1 p.N617K mutation or an ER stress-inducing form of thyroglobulin (Tg^cog^) ([@bib12]). Overall, the gene expression changes detected in all datasets shared some degree of similarity, and 227 genes were commonly changed, showing the activation of ER stress signaling in the MCDS chondrocytes, up-regulation of genes such as *Fgf21* and down-regulation of genes such as *Ldb3*. Differences were also found, and 473 genes were specifically changed in 13del, such as *Apoa4* (up-regulated) and *Atp2a1* (down-regulated) ([Supplementary file 4](#supp4){ref-type="supplementary-material"}). The differences from the published datasets may be due to the different mouse models, the time points analyzed (p14 versus 13del at p10), and also the methods of sampling the various chondrocyte populations. Those transcriptomes were derived from whole proliferative and hypertrophic zones, while ours were generated from precisely fractionated chondrocyte populations from the growth plate.

PERK-p-eIF2 signaling is the major contributor to chondrocyte adaptation to ER stress {#s2-2}
-------------------------------------------------------------------------------------

We investigated the contributions of the UPR arms, PERK, IRE1, and ATF6 to the HC response to ER stress. By ontology and pathway analyses of Cluster I, we found enrichment of genes in the PERK pathway and IRE1-Xbp1^S^ regulated ERAD, but not for ATF6 signaling ([Figure 1D and E](#fig1){ref-type="fig"}; [Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}; [Supplementary file 2](#supp2){ref-type="supplementary-material"} and [3](#supp3){ref-type="supplementary-material"}). Activation of PERK signaling in 13del HC was demonstrated by up-regulation of p-eIF2α and its downstream components (*Atf4, Atf3, Ddit3, Ero1l and Ppp1r15a*) ([Figure 1---figure supplement 2A and C](#fig1s2){ref-type="fig"}) which were validated by *in-situ* hybridization and immunostaining ([Figure 1---figure supplement 2B and C](#fig1s2){ref-type="fig"}). Using Motif enrichment analysis, we found that the binding motifs of CHOP (encoded by *Ddit3*) and ATF4 were highly enriched in Cluster I, but not those for Xbp1^S^ or ATF6 ([Figure 1F](#fig1){ref-type="fig"} and [Supplementary file 5](#supp5){ref-type="supplementary-material"}). By interrogating ATF4 and CHOP ChIP-seq data ([@bib27]), we found significant over-representation of ATF4 (odds ratio = 2.87, p\<0.0001) and CHOP (odds ratio = 4.33, p\<0.0001) binding peaks associated with the genes from Cluster I but not for the other clusters ([Supplementary file 6](#supp6){ref-type="supplementary-material"}). Cluster I genes are therefore most likely to be directly regulated by UPR-associated transcription factors.

Together, these data suggest a more prominent contribution of the PERK-p-eIF2 signaling pathway than that of Xbp1^S^, which is consistent with another MCDS mouse model study that found inactivation of Xbp1 in HCs did not alter the severity of dwarfism ([@bib11]). To test this notion, we ectopically expressed Xbp1^S^ in HCs in transgenic mice ([Figure 1---figure supplement 3A](#fig1s3){ref-type="fig"}). Overexpression of Xbp1^S^ specifically in HCs did not affect the growth plate ([Figure 1---figure supplement 3B and C](#fig1s3){ref-type="fig"}).

ATF4 expression in hypertrophic chondrocytes reprogrammes differentiation {#s2-3}
-------------------------------------------------------------------------

Apart from its role in the stress response, ATF4 is also required for chondrocyte differentiation through direct activation of *Ihh* ([@bib110]). In the E14.5-E17.5 fetal growth plate, ATF4 is expressed in differentiating chondrocytes, with the highest expression in pHCs ([Figure 2A](#fig2){ref-type="fig"}). ATF4 expression in HCs progressively decreases after birth and by p10 levels are especially lowered in the LHZ ([Figure 2A](#fig2){ref-type="fig"}). Therefore, the chondrocyte differentiation defects in the MCDS model might be directly caused by ectopic overexpression of ATF4 in HCs, as a consequence of the preferential translation of *Atf4* transcripts modulated by p-eIF2α.

![Ectopic activation of ATF4 in HCs recaptures the phenotypes of 13del mice.\
(**A**) Expression profiles of ATF4 (**a--f**) on the WT growth plates from E14.5 to P10 stages. Higher magnification of the boxed region (**a\'--f\'**) was shown to demonstrate the differential expression of ATF4 and the positive cells were arrowed. (Scale Bar = 200 μm) (**B**) Scheme of *Atf4* expressing vector. *Atf4* cDNA is inserted after the ATG codon in exon 2 of the *Col10a1*-Bac followed by an IRES-*Egfp* cassette. (**C**) Radiographic analysis revealed the dwarfism and skeletal abnormality of *C10-Atf4* mice at 4-month-old stage (n = 3). (**D**) Body lengths of the WT (n = 9) and *C10-Atf4* (n = 7) littermates were monitored from birth to 30-week stage, and a consistent reduction of body length in *C10-Atf4* mice was observed. (**E**) Abnormal proximal tibial growth plates with expanded HZ, delimited by dotted lines, were observed in *C10-Atf4* mice by Alcian Blue staining. (Scale bar = 200 μm). (**F**) Ectopic expression of *Atf4* in HCs was insufficient for ER stress response induction, indicated by *in-situ* hybridization of ER stress markers (*Hspa5, Atf3* and *Ddit3*). (Scale bar = 200 μm).](elife-37673-fig2){#fig2}

To assess the impact of ATF4 overexpression in HCs in the absence of ER stress, we generated a transgenic mouse model carrying a *Col10-Bac-Atf4-*IRES*-Egfp* transgene (hereafter referred to as *C10-Atf4*) ([Figure 2B](#fig2){ref-type="fig"}), in which ATF4 expression was driven by the highly HC-specific promoter of *Col10a1 *([@bib60]; [@bib118]). We confirmed HC-specific expression of the *C10-Atf4* transgene in the developing growth plates from fetal (E15.5) to adult (p20) stages ([Figure 2---figure supplement 1A and B](#fig2s1){ref-type="fig"}). Similar to 13del mice, adult *C10-Atf4* transgenic mice were dwarfs, being approximately 20% shorter than wild-type littermates ([Figure 2C and D](#fig2){ref-type="fig"}). Histological analyses revealed growth plate abnormality in both the appendicular and axial skeleton. These defects are illustrated by the greater than three-fold expansion of the HZ of the tibia and vertebrae of *C10-Atf4* mice ([Figure 2E](#fig2){ref-type="fig"}; [Figure 2---figure supplement 1C and D](#fig2s1){ref-type="fig"}). Interestingly, the HZ expansion is more severe in *C10-Atf4* mice (threefold of WT) than that in 13del (2.5-fold of WT), which is paralleling to the expression level of ATF4. Although forced expression of ATF4 in fibroblasts was reported to decrease survival ([@bib27]), cell viability was not affected in *C10-Atf4* mice ([Figure 2---figure supplement 1E](#fig2s1){ref-type="fig"}). Importantly, overexpression of ATF4 in HCs in the absence of ER stress did not induce transcription of the UPR-associated genes *Hspa5* and *Ddit3* ([Figure 2F](#fig2){ref-type="fig"}), although *Atf3* was slightly upregulated ([@bib27]). Therefore, activation of ATF4 alone, in the absence of the ER stress response, is sufficient to alter HC differentiation, disturb endochondral ossification and cause skeletal abnormalities similar to those observed in 13del mice.

ATF4 reprograms chondrocyte hypertrophy by directly activating *Sox9* {#s2-4}
---------------------------------------------------------------------

In *C10-Atf4* HCs, constitutive ATF4 activation down-regulated the expression of *Col10a1* and led to persistent expression of prehypertrophic chondrocyte marker genes *Sox9, Col2a1*, *Ppr* and *Ihh* in the HZ ([Figure 3A](#fig3){ref-type="fig"}). However, BrdU-labeled HCs were not detectable in the *C10-Atf4* HZ after 2 hr ([Figure 2---figure supplement 1F](#fig2s1){ref-type="fig"}), suggesting *C10-Atf4* HCs did not appear to have progressed through the G~1~/S checkpoint. The sequential differentiation process in growth plate chondrocytes is tightly regulated by multiple chondrocyte-specific transcription factors that control the expression of cell type-specific genes and secreted growth factors ([@bib38]; [@bib60]; [@bib102]; [@bib52]; [@bib43]; [@bib1]; [@bib64]). We searched the published ER stress-associated ATF4 ChIP-Seq data ([@bib27]) for binding peaks in crucial chondrogenic transcription factor genes, including members of SOX, RUNX, MEF2, GLI and FOXA families. We found ATF4 binding peaks in the regulatory regions of *Sox9, Sox5, Sox6, Runx2, Gli2* and *Gli3*. Amongst these, only the *Sox* genes were up-regulated in 13del middle and lower zones, but not *Gli2 or Gli3* ([Figure 3---figure supplement 1A and B](#fig3s1){ref-type="fig"}), suggesting that the *Sox* family could be the targets of ATF4. Notably, overexpression of *Sox9* in HCs resulted in an expansion of HZ and impaired terminal differentiation of HCs, similar to the phenotypes observed in *C10-Atf4* mice ([@bib34]). Moreover, the expression pattern of SOX9 paralleled that of ATF4 in 13del and *C10-Atf4* mice, raising the possibility of a direct interaction between these two factors as part of the molecular mechanism underlying the MCDS pathology.

![ATF4 governs de-differentiation of HCs via direct regulation of *Sox9.*\
(**A**) Ectopic expression of *Atf4* in HCs leads to accumulation of premature chondrocytes in *C10-Atf4* HZ, indicated by expression patterns of chondrogenic markers *Col10a1* (**a, a', b, b'**), *Sox9* (**c, c', d, d'**)*, Col2a1 *(e, (**e', f, f'**), *Ppr* (**g, g', h, h'**) and *Ihh *(i, (**i', j, j'**) (Scale bar = 200 μm). (**B**) Luciferase activities of reporters driven by *Sox9* promoter with different lengths (pSox9-2.7K, pSox9-1.8K, and pSox9-0.8K) (**i**) or ATF4 putative binding sites mutants (pSox9-1.8M1, pSox9-1.8M2 and pSox9-1.8M3) (ii) responding to different dosages of ATF4 were measured in ATDC5 cells and results were presented as fold induction compared with mock-transfected cells from three independent experiments. Error bars were shown as S.D. and significance was determined by unpaired Two-tailed Student's *t*-test. \*: p-value\<0.05, \*\*: p-value\<0.005, \*\*\*: p-value\<0.0005. (**C**) ChIP-PCR showed the direct binding of ATF4 to the putative motif on the *Sox9* promoter in vivo, using the nuclear extracts from E15.5 WT and *C10-Atf4* limb chondrocytes. Three independent experiments were performed and one presentative result was shown. An ATF4 ChIP-seq peak (dark triangle) around this region has been identified in ER-stressed MEF cells.](elife-37673-fig3){#fig3}

SOX9 is highly expressed in immature chondrocytes, transactivates critical cartilaginous matrix genes and regulates chondrocyte proliferation, differentiation and entry into hypertrophy ([@bib60]; [@bib1]; [@bib64]; [@bib6]; [@bib20]). It is required for expression of SOX5 and SOX6, which cooperate with SOX9 to transactivate *Col2a1 *([@bib57]; [@bib63]). We identified two putative C/EBP-ATF4 motifs, named A1 and A2, in the ATF4-binding peak in the *Sox9* promoter region. By transfection assays in ATDC5 chondrocyte cells, we found ATF4 could transactivate luciferase reporters controlled by the *Sox9* promoter ([Figure 3B](#fig3){ref-type="fig"}). Mutation of A1 and A2 respectively reduced or abolished ATF4 activation of the *Sox9* reporters ([Figure 3B](#fig3){ref-type="fig"}). Anti-ATF4 ChIP-PCR assays, using nuclear extracts from E15.5 wild-type and *C10-Atf4* limbs, demonstrated that ATF4 binds directly to the putative motif region on the *Sox9* promoter in vivo ([Figure 3C](#fig3){ref-type="fig"}).

We next assessed the contribution of ATF4 activation of *Sox9* in reverting HC differentiation by conditionally inactivating *Sox9* in *C10-Atf4* HC, using HC-specific Col10a1-Cre ([@bib118]) ([Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}). In the absence of *Sox9*, the expansion of HZ in *C10-Atf4* mice was markedly reduced, and there were fewer cells expressing *Col2a1* in the HZ ([Figure 4A--C](#fig4){ref-type="fig"}). Moreover, conditional inactivation of *Sox9* in 13del mice decreased expression of *Col2a1* and *Ppr* in HC, and the HZ expansion was considerably shortened ([Figure 4D--F](#fig4){ref-type="fig"}; [Figure 4---figure supplement 1B and C](#fig4s1){ref-type="fig"}). Deletion of *Sox9* in wild-type HCs did not affect chondrocyte hypertrophy ([Figure 4---figure supplement 1D](#fig4s1){ref-type="fig"}). Collectively, these data suggest ER stress-induced overexpression of ATF4 reverts differentiation in 13del HC by direct activation of *Sox9* in HCs, thereby perturbing chondrocyte hypertrophy.

![Genetic rescue of growth plate abnormalities in *C10-Atf4* and 13del mice via HC-specific inactivation of *Sox*9.\
(**A**) Removal of *Sox9* in *C10-Atf4* HCs rescued growth plate abnormalities of *C10-Atf4* mice at p10 stage, shown by histology (**a, a'**), expression analyses of SOX9 (**b, b', c, c'**)*, Col2a1* (**d, d'**) and *Col10a1* (**e, e\'**). Higher magnification of the boxed region was shown to demonstrate the differential expression of SOX9 and the positive cells were indicated by arrows. (Scale bar = 200 μm). (**B**) Measurement of the HZ lengths of *C10-Atf4* and *C10-Atf4;Sox9^C/C^* littermates (n = 5). The vertical length of the central part of the HZ from 10 different sections of each mouse was averaged. (**C**) Quantification of *Col2a1* positive cells in HZ of *C10-Atf4* and *C10-Atf4; Sox9^C/C^* littermates (n = 5). For each mouse, the number of positive cells was counted and average on five non-adjacent sections. (**D**) Removal of *Sox9* in 13del HCs rescued growth plate abnormalities of 13del mice at p10 stage (n = 5), shown by histology (**a, a'**), expression analyses of SOX9 (**b, b', c', c'**)*, Col2a1* (**d, d'**) and *Col10a1* (**e, e\'**). Higher magnification of the boxed region was shown to demonstrate the differential expression of SOX9 and the positive cells were arrowed. (Scale Bar = 200 μm). (**E**) Measurement of the HZ lengths of 13del and 13del*;Sox9^C/C^* littermates (n = 5). The vertical length of the central part of the HZ from 10 different sections of each mouse was averaged. (**F**) Quantification of *Col2a1* positive cells in HZ of 13del and 13del*;Sox9^C/C^* littermates (n = 5). For each mouse, the number of positive cells was counted and average on five non-adjacent sections. Error bars were shown as S.D. and significance was determined by Two-tailed Mann-Whitney *U*-test. \*: p-value\<0.05, \*\*: p-value\<0.005, \*\*\*: p-value\<0.0005.](elife-37673-fig4){#fig4}

CHOP plays an adaptive and pro-survival role in 13del HC {#s2-5}
--------------------------------------------------------

CHOP is another prominent transcription factor that was active in 13del HCs, revealed by bioinformatics analysis. It is preferentially expressed in the PERK signaling pathway, downstream of p-eIF2α and ATF4, which regulates protein synthesis via the PPP1R15A negative feedback loop and restores protein synthesis and induces oxidative stress via *Ero1l* ([@bib27]; [@bib67]). Apart from that, overexpression of CHOP in the bone microenvironment in transgenic mice has been reported to impair osteoblastic function leading to osteopenia ([@bib81]), while CHOP null mice show retarded bone formation ([@bib80]), indicating its role in regulating osteoblast differentiation. Although CHOP is widely considered as a pro-apoptotic factor, it has context- and cell-type specific roles as an adaptive and pro-survival factor in several diseases ([@bib79]; [@bib101]; [@bib65]; [@bib71]). Forced expression of ATF4 and CHOP has been reported to increase cell death ([@bib33]). We, therefore, assessed the contribution of CHOP in the adaptation of 13del HCs.

We found ablating CHOP encoding gene *Ddit3* in 13del mice exacerbated the skeletal defects and growth plate phenotype. The 13del;*Ddit3*^-/-^ mice displayed further tibial shortening ([Figure 5A and B](#fig5){ref-type="fig"}) with more significant (\~20%) HZ expansion ([Figure 5C and D](#fig5){ref-type="fig"}), and increased the number of chondrocytes expressing immature chondrogenic markers SOX9, *Col2a1* and *Ppr* in the HZ ([Figure 5C and E](#fig5){ref-type="fig"}). Strikingly, in contrast to 13del, there was increased apoptosis in 13del;*Ddit3*^-/-^ HC, consistent with a pro-survival role for CHOP ([Figure 5F and G](#fig5){ref-type="fig"}).

![CHOP limits the deleterious consequence of ER Stress in 13del mice.\
(**A--B**) The tibia length is further shortened in 13del;*Ddit3^-/-^* mice at the p10 stage. The comparison was performed between 13del and 13del;*Ddit3^-/-^* littermates (n = 5). (**C**) Exacerbated growth plate abnormalities were observed in 13del mice with global loss of *Ddit3* at p10 stage (n = 5), shown by histology (**a, a'**), expression analyses of *Col10a1* (**b, b'**), SOX9 (**c, c', d, d'**)*, Col2a1* (**e, e'**) and *Ppr* (**f, f\'**). Higher magnification of the boxed region was shown to demonstrate the differential expression of SOX9 and the positive cells were indicated by arrows. (Scale Bar = 200 μm) (**D**) Measurement of the HZ lengths of 13del and 13del;*Ddit3^-/-^* littermates (n = 5). The vertical length of the central part of the HZ from 10 different sections of each mouse was averaged. (**E**) Quantification of SOX9, *Col2a1* and *Ppr*-positive cells in HZ of 13del and 13del;*Ddit3 ^-/-^* littermates (n = 5). For each mouse, the number of positive cells was counted and average on five non-adjacent sections. (**F--G**) TUNEL assay revealed an increased number of apoptotic cells in 13del;*Ddit3^-/-^* HZ (n = 5). Arrows indicate TUNEL-positive cells. (Scale Bar = 200 μm). For each mouse, the number of positive cells was counted and average on five non-adjacent sections. Error bars were shown as S.D. and significance was determined by Two-tailed Mann-Whitney *U*-test. \*: p-value\<0.05, \*\*: p-value\<0.005, \*\*\*: p-value\<0.0005.](elife-37673-fig5){#fig5}

Our transcriptome analyses of fractionated 13del;*Ddit3^-/-^* growth plates revealed upregulation of molecular chaperones (*Hspa5, Dnajb9, Dnajb11* and *Canx*) and ER stress sensors (*Xbp1* and *Atf4*) in the MHZ and LHZ ([Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}), which further support the positive correlation between the phenotype severity and the expression level of ATF4. In contrast to the elevated stress level, the PERK signaling pathway was enfeebled, reflected by marked (\>3.5 fold) down-regulation of CHOP targets *Atf3, Ppp1r15a* and *Ero1l,* indicating the phenotype severity reflected by aberrant cell differentiation is probably independent of those downstream factors. These results are in contrast to the pro-apoptotic role reported for CHOP in a mouse model of Pseudoachondroplasia caused by expression of misfolded COMP in proliferating and hypertrophic chondrocytes, where deleting CHOP reduced apoptosis but exacerbated growth plate chondrocyte disorganisation ([@bib85]; [@bib82]). These differences may be due to variation in the responses of proliferating versus hypertrophic chondrocytes and/or the acuteness and duration of the ER stress. Therefore, CHOP aids in the cell adaptation to stress and mediates survival in13del HC, and it is important to identify pro-survival/anti apoptotic factor(s) downstream of CHOP.

ATF4 and CHOP mediate chondrocyte survival by activating *Fgf21* {#s2-6}
----------------------------------------------------------------

CHOP acts, not only downstream of ATF4 but also as its interacting partner in modulating ER stress targets ([@bib27]). To elucidate the pro-survival role of the PERK signaling pathway in 13del HC, we searched for target genes of CHOP and ATF4 in Cluster I ([Supplementary file 6](#supp6){ref-type="supplementary-material"}). We found *Fgf21*, a reported target of ATF4 (65), was the most upregulated gene in 13del HCs ([Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"} and [Supplementary file 1](#supp1){ref-type="supplementary-material"}), which was confirmed by *in-situ* hybridization and immunoblotting ([Figure 6A](#fig6){ref-type="fig"}). *Fgf21* has been reported to be similarly activated in ER-stressed chondrocytes ([@bib12]).

![*Fgf21* is regulated by ATF4 and CHOP.\
(**A**) Significant activation of *Fgf21* in 13del HCs at the p10 stage, revealed by *in-situ* hybridization (**a, b**) and western blot (**c**) (Scale Bar = 200 μm). (**B**) Ectopic expression of *Atf4* (**a, a'**) is insufficient for *Fgf21* (**b, b'**) induction in HCs (Scale Bar = 200 μm). (**C**) ChIP-PCR showed the binding of ATF4 and CHOP to the putative motif on the *Fgf21* promoter under ER stress in NIH3T3 cells. (**D**) Normalized microarray measurement of *Fgf21* in WT, 13del and 13del;*Ddit3^-/-^* chondrocytes. (**E--F**) FGF21 protects the 13del HCs from apoptosis in a dosage-dependent manner. Arrows indicate TUNEL-positive cells. The quantification of TUNEL positive cells was performed between littermates (n = 5). For each mouse, the number of positive cells was counted and averaged on five non-adjacent sections. (Scale Bar = 200 μm) Error bars were shown as S.D. and significance was determined by Two-tailed Mann-Whitney *U*-test. \*: p-value\<0.05, \*\*: p-value\<0.005, \*\*\*: p-value\<0.0005.](elife-37673-fig6){#fig6}

FGF21 is a hormone with roles in glucose and lipid metabolism ([@bib50]) and plays a survival role in response to diverse stressful conditions, such as amino acid deprivation, mitochondrial stress and ER stress-associated diseases such as diabetes, cardiovascular diseases (reviewed in \[[@bib23]; [@bib51]; [@bib94]\]). We found *Fgf21* expression was effectively turned on (\>100 fold increased expression) in response to treatment with the ER stress inducer tunicamycin in fibroblasts (NIH3T3 and MEF cells) and ATDC5 cells ([Figure 6---figure supplement 1B and C](#fig6s1){ref-type="fig"}).

We next tested the functional relevance of a reported C/EBP-ATF4 binding motif in the *Fgf21* promoter ([@bib27]) that coincided with an ATF4 peak. By transactivation assays ([Figure 6---figure supplement 1D](#fig6s1){ref-type="fig"}), we found deleting (pFgf21-Luc3 and pFgf21-Luc4) or mutating (pFgf21-M1 and pFgf21-M3) the ATF4 binding motif abolished the activation induced by ER stress. However, *Fgf21* was not induced in *C10-Atf4* mice ([Figure 6B](#fig6){ref-type="fig"}), suggesting ATF4 is necessary but not sufficient for *Fgf21* induction. The need for another factor is supported by the ChIP assays where we found both ATF4 and CHOP bind to the ATF4 motif-containing peak region in the cells under ER stress ([Figure 6C](#fig6){ref-type="fig"}), even though no CHOP binding peak was detected in the *Fgf21* promoter. Expression of *Fgf21* was down-regulated by approximately 40% in 13del;*Ddit3^-/-^* HC despite the upregulation of *Atf4* ([Figure 6D](#fig6){ref-type="fig"}), consistent with the requirement of ATF4-CHOP cooperation for *Fgf21* induction under ER stress.

We assessed whether FGF21 had a survival role in 13del HC by genetically ablating the gene ([Figure 7---figure supplement 1A](#fig7s1){ref-type="fig"}). *Fgf21* null mice have normal growth plates and HC viability ([Figure 7---figure supplement 1B and C](#fig7s1){ref-type="fig"}). The HZ expansion in 13del*;Fgf21^-/-^* mice was comparable to that of 13del mice, and the reverted differentiation process was not affected ([Figure 7---figure supplement 1D--F](#fig7s1){ref-type="fig"}). However, we found increased apoptosis in the HZ of *Fgf21*-deficient 13del mice, and this protective effect of FGF21 is dosage dependent ([Figure 7Aand B](#fig7){ref-type="fig"}).

![FGF21 protects the HCs from ER stress-induced apoptosis in a cell autonomous manner.\
(**A--B**) FGF21 protects the 13del HCs from apoptosis in a dosage-dependent manner. Arrows indicate TUNEL positive cells. The quantification of TUNEL-positive cells was performed between littermates (n = 5). For each mouse, the number of positive cells was counted and averaged on five non-adjacent sections (Scale Bar = 200 μm). (**C**) Schematic diagram of 13del;*Col10a1^Egfp^/*13del;*Fgf21^-/-^* chimera generation. In chimeric HZ, 13del HCs expressing *Fgf21* (13del;*Col10a1^Egfp^)* can be distinguished from 13del;*Fgf21^-/-^* HCs by EGFP expression. (**D**) The number of TUNEL-positive cells was quantified in GFP^+^ and GFP negative HCs (n = 7). Error bars were shown as S.D. and significance was determined by Two-tailed Mann-Whitney *U*-test. \*: p-value\<0.05, \*\*: p-value\<0.005, \*\*\*: p-value\<0.0005. (**E**) The correlation between cell death and chimerism (indicated by the percentage of 13del-EGFP expressing cells in HZ) in 13del*;Col10a1^Egfp^*/13del;*Fgf21^-/-^* chimeras. (**F**) Boxed region (**a**) is shown to demonstrate the differential localization of EGFP and TUNEL signal in chimeric HZ. Higher magnification is shown in b-d. Immunostaining for FGF21 and TUNEL assays (**e--h**) were applied on the chimeric growth plate, showing the mutually exclusive location of FGF21 (green) and TUNEL signal (red).](elife-37673-fig7){#fig7}

To determine whether the pro-survival role of FGF21 was cell autonomous or non-cell autonomous in 13del HCs, we tested the survival of 13del HCs carrying an *Fgf21* null mutation, in mouse chimeras. We utilised compound mutants carrying the 13del transgene and a *Col10a1^Egfp^* allele \[*Egfp* knocked into the *Col10a1* gene ([@bib118])\] so that all 13del HCs are marked by GFP expression. We created mouse chimeras by aggregating 13del;*Col10a1^Egfp^* and 13del;*Fgf21^-/-^* morulae ([Figure 7C](#fig7){ref-type="fig"}). In the ensuing chimeras, 13del HCs are marked by EGFP expression, and express *Fgf21*/FGF21. Mice with different degrees of 13del;*Col10a1^Egfp^*/13 del;*Fgf21^-/-^* chimerism, were analyzed for HC survival. Similarly as found with 13del;*Fgf21^-/-^* compound mutants, in 13del;*Col10a1^EGFP^*/13 del*;Fgf21^-/-^* chimeras, more 13del*;Fgf21^-/-^* HCs (non-EGFP^+^ HC population) underwent apoptosis, than the 13del; *Col10a1^Egfp^* HCs (GFP^+^ HC population) ([Figure 7D](#fig7){ref-type="fig"}). Moreover, there was a positive correlation between the contribution of13del;*Col10a1^Egfp^* HCs and the number of surviving cells in the HZ ([Figure 7E](#fig7){ref-type="fig"}), consistent with a protective role for FGF21 in the ER-stressed 13del HCs. Furthermore, we found that *13del;Fgf21^-/-^* HCs adjacent to *13del;Col10a1^Egfp^* HCs expressing *Fgf21* still underwent apoptosis ([Figure 7F](#fig7){ref-type="fig"}). This inability of *13del;Col10a1^Egfp^* to rescue *13del;Fgf21^-/-^* HCs suggests that FGF21 protects HCs from apoptosis, cell autonomously.

ISRIB, an ISR p-eIF2α signaling inhibitor, can ameliorate 13del skeletal deformities {#s2-7}
------------------------------------------------------------------------------------

Upon ER stress, PERK phosphorylation of eIF2α is the critical upstream controlling point that triggers the p-eIF2α/ATF4/CHOP signaling pathway ([@bib78]). Our data show that genetically ablating the essential transcription factor CHOP in the p-eIF2α signaling pathway as a strategy for rescuing the aberrant chondrocyte differentiation is imperfect, because of effects on cell survival and stress aggravation. Also, addressing the impact of transcription factor overexpression and cell-type specificity is required because ATF4 is essential for normal development. Therefore, it is necessary to identify a suitable entry point in the pathway which can be manipulated for protection or rescue from the deleterious effects of ER stress, without interfering with normal developmental function.

Recently, a small molecule, Integrated Stress Response InhiBitor (ISRIB) has been reported to be a potent ISR signaling inhibitor, rendering cells insensitive to eIF2α phosphorylation by targeting the interaction between eIF2 and eIF2B, and its activity is independent of eIF2a phosphorylation ([@bib96]; [@bib99]). ISRIB shows acceptable pharmacokinetic properties and no overall toxicity in mice and has been reported to show significant neurotrophic effects in mice ([@bib96]; [@bib19]).

We tested the potential of ISRIB to modify the chondrodysplasia phenotype by treating 13del and wild-type littermates with ISRIB (2.5 mg/kg) or vehicle twice daily by intraperitoneal injection from E13.5 (onset of expression of 13del) to postnatal day 20 (p20) ([Figure 8A](#fig8){ref-type="fig"}). In wild-type mice, ISRIB had no adverse effects on weight gain or body growth ([Figure 8---figure supplement 1A and B](#fig8s1){ref-type="fig"}). However, ISRIB markedly reduced the dwarfism of 13del mice from newborn to juvenile stages comparing to control group ([Figure 8---figure supplement 1C](#fig8s1){ref-type="fig"}). Radiographic analyses revealed treatment with ISRIB ameliorated the skeletal deformities at p20 ([Figure 8B and C](#fig8){ref-type="fig"}), including the length of tibia/femur and spine; tibia bowing (*genu varum*: the angle between proximal head and distal head of tibia); pelvic bone orientation (the angle between ilium and pubis), and *coxa vara* (narrowed angle between the proximal head and the shaft of the femur) ([Figure 8B](#fig8){ref-type="fig"}).

![The small molecule ISRIB, preventing ATF4 induction under ER stress, ameliorates *13del* skeletal deformities.\
(**A**) Schematic timeline of the ISRIB (2.5 mg/kg) or vehicle (0.5% DMSO in 0.9% saline) administration. The mice were administrated by intraperitoneal injection, starting from E13.5 to the p20 stage. The animals were harvested at indicated time-points. (**B--C**) Radiographic analyses revealed skeletal deformities of 13del mice were alleviated at p20 stage by ISRIB treatment (n = 3), including length of tibia, femur and spine (spine here indicated by the length of 7 continuous vertebrae consisting of the last sacral and six tail vertebrae), pelvic bone deformation (*θ1*: the angle between ilium and pubis), *Coxa Vara* (*θ2*: the angle between the proximal head and the shaft of the femur) and *Genu Varum* (*θ3*: the angle between proximal head and distal head of tibia). The skeletal phenotypes in vehicle- and ISRIB-treated 13del groups were compared, and the significance of changes was determined by one-way ANOVA test. \*: p-value\<0.05, \*\*: p-value\<0.005, \*\*\*: p-value\<0.0005. (**D--E**) Rescue of growth plate abnormalities in 13del mice by the treatment of ISRIB at the p10 and p20 stages, shown by histology (**a--a\"**) and in vivo expression profiles of SOX9 (**b--b" and c--c"**)*, Col2a1* (**d--d"**) and *Ppr* (**e--e\'\'**). Higher magnification of the boxed region was shown to demonstrate the differential expression of SOX9 and the positive cells were indicated by arrows. (Scale Bar = 200 μm). (**F**) Measurement of the HZ lengths of tested animals at p10 stage (n = 5) and p20 stage (n = 3). The vertical length of the central part of the HZ from 10 different sections of each mouse was averaged. (**G**) Quantification of SOX9^+^, *Col2a1^ +^* and *Ppr^ +^* cells in HZ of tested animals at p10 stage (n = 5) and p20 stage (n = 3). For each mouse, the number of positive cells was counted and average on five non-adjacent sections. Error bars were shown as S.D. and significance was determined by Two-tailed Mann-Whitney *U*-test. \*: p-value\<0.05, \*\*: p-value\<0.005, \*\*\*: p-value\<0.0005.](elife-37673-fig8){#fig8}

We found the HZ expansion in the limb growth plates of ISRIB-treated 13del mice was significantly reduced, and the numbers of SOX9^+^, *Col2a1*^+^ and *Ppr*^+^ cells in the HZs at p10 and p20 were diminished ([Figure 8D--G](#fig8){ref-type="fig"}). ISRIB with indicated dosage had no observable effect on the limb growth plates in wild-type mice ([Figure 8---figure supplement 1D](#fig8s1){ref-type="fig"}). ISRIB treatment in 13del mice also reduced the deformities in other growth plates such as in the axial skeleton, with reduced HZ expansion and decreased the number of *Sox9*^+^ and *Col2a1*^+^ premature cells in tail intervertebral disc growth plates ([Figure 8---figure supplement 2A--C](#fig8s2){ref-type="fig"}).

Furthermore, the effectiveness of postnatal treatment of ISRIB in 13del MCDS was estimated by treating 13del and wild-type littermates with ISRIB (2.5 mg/kg or 5 mg/kg) or vehicle twice daily by intraperitoneal injection from newborn (p0) to 4-week stages ([Figure 8---figure supplement 3A](#fig8s3){ref-type="fig"}). Similarly, ISRIB ameliorated the dwarfism of 13del mice from newborn to 4-week stages in a dosage-dependent manner ([Figure 8---figure supplement 3B](#fig8s3){ref-type="fig"}), and ameliorated the skeletal deformities ([Figure 8---figure supplement 3C and D](#fig8s3){ref-type="fig"}), including the length of tibia/femur and spine; tibia bowing; pelvic bone orientation and *coxa vara,* revealed by radiographic analyses. Thus, without any apparent adverse effect, ISRIB corrected the molecular, histological, and skeletal defects in 13del mice.

The PERK-p-eIF2α signaling pathway is downregulated explicitly by treatment of ISRIB {#s2-8}
------------------------------------------------------------------------------------

The impact of ISRIB on p-eIF2α signaling induced by ER stress in 13del HCs was further addressed. Consistent with the previous study ([@bib98]) that the activity of ISRIB is independent of eIF2α phosphorylation ([@bib96]; [@bib99]), the expression of p-eIF2α was not affected in ISRIB-treated 13del HCs ([Figure 9A](#fig9){ref-type="fig"}). Given the fact that translational regulation of ATF4 by p-eIF2α is central to the activation of PERK signaling, the protein expression level of ATF4 in p10 vehicle-treated WT, vehicle- and ISRIB-treated 13del HCs were examined via immunoblotting. As expected, ISRIB evidently inhibited the preferential translation of ATF4 in ER-stressed 13del HCs ([Figure 9B](#fig9){ref-type="fig"}). The proximal growth plates from above mentioned groups of mice were further fractionated into sub-populations (PC, pHC, UHC, MHC, and LHC), and the transcriptional expression levels of major components of p-eIF2α signaling (*Atf4, Atf3, Ddit3* and *Fgf21)*, *Xbp1^S^* and *Hspa5* (*Bip)* were examined by qRT-PCR. Consistently, ISRIB treatment significantly downregulated the mRNA expression level of *Atf3* and *Ddit3* in 13del HCs, indicating the downstream signaling cascade of ATF4 were inhibited ([Figure 9C](#fig9){ref-type="fig"}), although the expression level of *Atf4* was not affected. The expression patterns and levels of examined factors involved in the p-eIF2α signaling pathway were further validated via *in-situ* hybridization and immunostaining ([Figure 9---figure supplement 1A and B](#fig9s1){ref-type="fig"}). Notably, the expression of CHOP and FGF21 was significantly lowered but still detectable. On the other hand, the expression level of total *Xbp1* (*Xbp1^T^*) and spliced *Xbp1* (*Xbp1^S^*) in ISRIB-treated 13del HCs was comparable to vehicle-treated HCs, indicating IRE1/Xbp1 signaling was barely affected and confirmed the selectivity of ISRIB action ([Figure 9C](#fig9){ref-type="fig"}). Thus, the effects of ISRIB on ameliorating 13del MCDS phenotype is Xbp1^S^-independent, and it further supports the redundancy of IRE1/Xbp1 signaling in the pathogenesis of MCDS ([@bib11]). Also, the transcriptional and translational expression levels of ER chaperone BiP(encoded by* Hspa5*) were relatively attenuated in ISRIB-treated 13del HCs ([Figure 9B and C](#fig9){ref-type="fig"}), consistent with previous studies showing that PERK-p-eIF2α signaling is required for the activation of BiP upon ER stress ([@bib28]; [@bib95]). Immunostaining with a 13DEL-specific antibody revealed the 13DEL mutant protein were intracellularly accumulated in ISRIB-treated 13del HCs ([Figure 9---figure supplement 1C](#fig9s1){ref-type="fig"}), indicating the production and/or degradation of the mutant protein was not affected. Interestingly, inhibition of p-eIF2α signaling by ISRIB at indicated dosage did not induce apoptosis ([Figure 9---figure supplement 1D](#fig9s1){ref-type="fig"}) in 13del HCs, with a lowered expression level of ATF4, CHOP and FGF21. This finding highlights the importance of level titration of these factors in the prevention of de-differentiation without causing the death of the stressed chondrocytes. Thus, the effects of ISRIB on ameliorating 13del MCDS phenotype depends explicitly on downregulating p-eIF2α modulated ATF4 induction and its downstream target SOX9.

![The PERK-p-eIF2α signaling pathway is specifically down-regulated by the treatment of ISRIB in 13del HCs.\
At p10 stage, the expression of p-eIF2α in ISRIB-treated 13del HC was not changed. Higher magnification of the boxed region was shown to demonstrate the expression of p-eIF2 clearly, and the positive staining cells were indicated by arrows. (Scale Bar = 200 μm) (**B**) The vehicle-treated WT, vehicle- and ISRIB-treated 13del p10 HZ were equally fractionated into two chondrocyte populations (UHC and LHC), and protein from each population was isolated. The protein expression level of ATF4 and ER stress sensor BiP were examined via western blot. Beta-actin was used as internal control. (**C**) The WT, vehicle- and ISRIB-treated 13del p10 growth plates were fractionated into different chondrocyte populations (PC, pHC, UHC, MHC and LHC), and total RNA from each population was isolated. The expression levels of *Atf4,* its downstream targets (*Atf3, Ddit3,* and *Fgf21)*, ER stress sensor *Hspa5*, total *Xbp1^T^* and its active form *Xbp1^S^* were quantified via qRT-PCR, results were presented as fold induction compared with WT proliferating chondrocytes (PC) from five independent animals of each group. Error bars shown as S.D. and significance between vehicle- and ISRIB-treated HCs was determined Two-tailed Mann-Whitney *U*-test. \*: p-value\<0.05, \*\*: p-value\<0.005.](elife-37673-fig9){#fig9}

Discussion {#s3}
==========

In this study, we have exploited an *in vivo* model of a congenital developmental disorder and provided mechanistic insight into the question of how the ISR impacts on cell differentiation and fate and importantly, also addressed the possibility of preventive therapy. Our study on a MCDS mouse model demonstrates a direct link between the ISR component of the UPR, PERK-p-eIf2α signaling, and its dominant role in causing reprogrammed chondrocyte differentiation and in mediating their survival. Our study highlights the causative role*, in vivo*, of p-eIF2a induced ATF4 overexpression in HCs, in controlling cell differentiation and survival ([Figure 10](#fig10){ref-type="fig"}). Given the key roles of SOX9 as an essential modulator in regulating chondrocyte differentiation, proliferation and entry into hypertrophy ([@bib60]; [@bib1]; [@bib64]; [@bib20]), ATF4-directed transactivation of *Sox9* in HCs where it is not normally expressed, implicates its ectopic expression as the cause of HC reversion to a less differentiated state. Consistent with this possibility is the amelioration of aberrant chondrocyte differentiation when *Sox9* is conditionally ablated in 13del and *C10-Atf4* mice. Ectopic expression of SOX9 can reprogram fibroblasts to chondrogenic fate ([@bib37]), and also acts in a dosage-dependent manner with effects of ectopic overexpression in HCs, ranging from mild expansion of the HZ ([@bib60]) to increased apoptosis, defects in vascular invasion and reduced trabecular bone ([@bib34]). Therefore, the impact of the ISR on chondrocyte fate likely depends on the intensity of the ISR and degree of overexpression of SOX9 and chondrocyte differentiation stage.

![A schematic model for PERK signaling pathway in modulating skeletal phenotype in MCDS 13del mice.\
ISRIB eased the MCDS symptoms by inhibiting the ectopic expression of ATF4, induced by inactive eIF2(p)-eIF2B complex, and the consequent expression of *Sox9*.](elife-37673-fig10){#fig10}

It is interesting that we found that the Xbp1 component of the IRE1 arm of the UPR did not have a major role in causing reverted chondrocyte differentiation, suggesting differences in utilization of the UPR sensors and that choice of biochemical pathway in cellular response to ER stress may be context dependent. Such a possibility is consistent with another report where a osteogenesis imperfecta COL1A2 G610C mutation causes procollagen I misfolding in the ER of osteoblasts and abnormal osteoblast differentiation, but did not induce the classical UPR mediators BiP or *Xbp1*-spliced form ([@bib69]). Instead, an unconventional cell stress response was invoked, involving the increase in eIF2α phosphorylation and upregulation of CHOP, key components of the ISR. Although not demonstrated, that report suggests a mechanism for the abnormal osteoblast differentiation in osteogenesis imperfecta, given the link between eIF2α phosphorylation and preferential translation of transcripts encoding factors such as ATF4, a key regulator of osteoblast differentiation (reviewed in \[[@bib24]\]), and CHOP ([@bib97]), the ISR emerges as a likely effector of the abnormal osteoblast differentiation in osteogenesis imperfecta.

Human skeletal dysplasia lead to physical disabilities and generates difficulties in education, employment and social life ([@bib100]; [@bib105]). Current treatment options in skeletal disorders are insufficient and may involve controversial surgical procedures such as limb lengthening ([@bib62]). Growth hormone therapy has been used to treat dwarfism but is clarified to be ineffective for height gain in most congenital skeletal dysplasia, and in some cases with severe spinal deformities, it even results in worsened kyphosis and lordosis ([@bib47]), emphasizing the need for a deep understanding of the molecular pathogenesis for effective treatment development. One successful example is the pathogenic elucidation of FGFR3 signaling in achondroplasia (ACH) that led to an effective therapeutic regimen via antagonizing FGFR3 downstream signaling. Based on that, the C-type natriuretic peptide (CNP) analog (BMN111) treatment resulted in a substantial improvement in skeletal parameters in Fgfr3^Y367C/+^mice mimicking ACH and a clinical trial is underway ([@bib119]). In another case of PASCH, unremitting ER stress was demonstrated to be associated with a self-perpetuating pathological loop between ER stress, inflammation and oxidative stress process. Suppressing inflammation or oxidative stress by aspirin or resveratrol was shown to be effective in rescuing partially limb growth in a COMP mouse model of PSACH ([@bib84]).

Therefore, a more profound molecular pathogenic insight into the role of ER stress/ISR in MCDS might provide the basis of developing potential interventions to alleviate the skeletal deformities in this disorder. Early attempts using chemical chaperone sodium butyrate([@bib76]) or ER-stress reducing reagent lithium, valproate, or phenylbutyric acid (PBA) ([@bib86]) failed to rescue chondrodysplasia in mouse models. In a recent study, the pathological phenotype of another MCDS mouse model harboring *Col10a1* misfolded mutation was partially ameliorated by administration of carbamazepine (CBZ), a drug that induces mutant type X collagen breakdown ([@bib72]). Notably, CBZ treatment of MCDS mice reduced the stress level and attenuated the expression level of ATF4 in HCs ([@bib72]), consistent with our finding that the disease severity is positively correlated with the HC expression level of ATF4. However, how ER stress induced ATF4 expression causes the chondrocyte differentiation defect was not delineated.

Knowledge of the precise signaling pathway effector(s) that is critical for normal skeletal physiology and homeostasis, and mechanisms of causation for the aberrant cell differentiation associated with MCDS and other skeletal disorders is essential for the development of a targeted treatment strategy. Pharmacological inhibition of PERK or PERK-mediated phosphorylation of downstream targets has been reported to be neuroprotective ([@bib25]), addressing the postnatal impact of activating the PERK signaling in neurodegeneration and also highlights the importance of determining the precise mechanism of causality of this pathway under specific scenarios of degeneration versus cell differentiation in development ([@bib70]). Interestingly, a recent study identified a novel mechanism by which the GCN2-regulated ISR-p-eIf2α antagonizes Bone Morphogenetic Protein (BMP) signaling, although direct effects on translation and indirectly via *crc* (dATF4) during development in *Drosophila* ([@bib66]). Given the vital role of BMP in regulating multiple developmental processes in organisms from insects to mammals, including chondrocyte/osteoblast differentiation, our study adds to the growing evidence of the importance of the ISR not only in disease scenarios but in regulating normal differentiation and skeletal homeostasis. Taken together, it was therefore essential to address whether manipulating the PERK-p-eIf2α pathway in the scenario of a congenital abnormality caused by the deleterious impact of the ER stress/ISR on skeletal development, could be useful.

Our findings also illustrate the importance of where in the PERK pathway a therapeutic approach should be taken. Global inhibition of CHOP will not be effective because its inactivation exacerbates the defect. By the same token, given the importance of ATF4 to normal development simply preventing its expression globally would not work therapeutically. Instead, a viable approach would be to target the translational control that leads to its overexpression.

Here, we demonstrate that for a disorder that is caused by the impact of the p-eIF2α signaling on cell fate and differentiation during development, a practical therapeutic approach is to target early in pathway, at the level of p-eIF2α-mediated translation control by specific inhibitors, such as ISRIB ([Figure 10](#fig10){ref-type="fig"}). By that, we have shown that ISRIB enfeebled the induction of ATF4 and its downstream target SOX9, prevented the aberrant cell differentiation and consequential dwarfism without obvious side effects. Previously, the selectivity of ISIRIB in targeting translational control of p-eIF2α has been studied by different reports, where it has been used in studies in mice such as treatment of neurodegeneration ([@bib25]; [@bib116]), aggressive prostate cancer ([@bib74]), in enhancing memory and memory consolidation in mice ([@bib98]), cognitive deficits after traumatic brain ([@bib14]) and in rescuing impaired sociability and anxiety-like behavior ([@bib46]). ISRIB has also been used to address expression of OPHN1 as a translational downstream target of p-eIF2α that is associated with mGluR-LTD-linked cognitive disorders ([@bib19]). Here, the effect of ISRIB on the aberrant differentiation of ER-stressed HCs reveals its action on antagonizing preferential translation of ATF4, and consequent SOX9 induction to reverse or prevent the abnormal cell fate change in disease.

Interestingly, by the treatment of ISRIB at the indicated dosage, the enfeebled action of p-eIF2α did not induce apoptosis, with lowered but detectable expression of ATF4, CHOP and downstream target FGF21. This finding reveals, in the context of the 13del mutation, the dominance of dedifferentiation in the pathogenesis of MCDS. Notably, PERK was reported to have a role in pancreatic β cells under physiological ER stress conditions, via regulating β cell proliferation/development, proinsulin production/trafficking, insulin secretion and protecting the cells from tolerable ER stress in an ATF4-dependent manner. However, continuous eIF2α phosphorylation induces β cell death via activating ATF4-CHOP pathway ([@bib77]). These findings strongly suggest PERK/ISR signalling pathway may behave as a binary switch between life and death in organ homeostasis. By finding the dosage of ISRIB that titrates ATF4-CHOP levels and is protective for de-differentiation, without causing the death of the stressed chondrocytes, the dualism inherent in the PERK signaling may be exploited therapeutically. Our study may also reflect the possibility that other potential translational downstream target(s) of p-eIF2α may be involved in the cell death induction in 13del HCs upon stress and act upstream of CHOP and FGF21.

The inability of FGF21 expressing 13del HCs to protect 13del;*Fgf21^-/-^* HCs from apoptosis in mouse chimeras suggests FGF21 cell autonomously protects HCs from apoptosis. Interestingly, our microarray analyses show that *blk*, the gene encoding beta-klotho, which is required for FGF21-mediated receptor binding and activation ([@bib54]), is not expressed in 13del HCs, suggesting that ISR-induced FGF21 may function in a FGFR1/beta-klotho-independent manner to enable the HCs survival. The lack of *blk* expression in 13del HCs suggest the pro-survival role of FGF21 in ER stressed HCs could be non-canonical. It has been reported that FGF21 reduces the concentrations of the active form of STAT5, a major mediator of growth hormone actions, lowers the expression of IGF-1, but induces the expression of IGF-1 binding protein one to blunt growth hormone signaling ([@bib42]). Our microarray data show that the expression levels of these FGF21 targets were comparable between WT and 13del HCs. FGF21 is a biomarker for mitochondrial translation and mtDNA maintenance disorders, and a stress-induced myokine in mitochondrial diseases ([@bib58]). FGF21 is also proposed to be a critical metabolic mediator of ISR presumably causing systemic metabolic improvements ([@bib49]). Moreover, FGF21 has been reported to protect the mouse liver and brain against d-gal-induced oxidative stress and apoptosis via activating Nrf2 and PI3K/Akt pathways ([@bib122]; [@bib121]). Analyses of the proteome of 13del HCs has implicated the potential role of the ER-mitochondria pathway in chondrocyte survival by a mechanism whereby changes in ER-mitochondria communication reduce import of calcium coupled to maintenance of mitochondrial membrane polarity ([@bib53]). Our transcriptome data show that oxidative stress was triggered in 13del HCs ([Figure 1D and E](#fig1){ref-type="fig"}). It will therefore be important to study the intrinsic roles of ISR-induced FGF21 in mitochondria homeostasis and in regulating oxidative stress-related apoptosis.

It is also noteworthy that while ISRIB treatment significantly improved the pathological phenotype of 13del MCDS mice, mutant type X collagen was still detectable and therefore some residual ER stress was present. Consistent with residual ER stress in ISRIB-treated HCs is the persistent expression of ATF4, albeit at lowered levels, which may account for incomplete rescue. Likewise rescue by CBZ treatment was only partial ([@bib72]). It would be important in future to test whether a strategy of addressing both aberrant cell differentiation and enhancing mutant protein degradation by combined treatment with ISRIB and CBZ, could achieve complete rescue of MCDS and other skeletal disorders associated with the UPR/ISR. In addition, the relative poor solubility of ISRIB might have limited its bioavailability *in vivo*. A recent study of ISRIB treatment in prostate cancer model showed improved bioavailability of ISRIB by using HPMT vehicle solution (0.5% w/v hydroxypropyl-methylcellulose dissolved in water plus 0.2% v/v Tween80, adjusted to pH 4) ([@bib74]). For future studies, it would be important to test whether ISRIB dissolved in HPMT will result in improved alleviation of MCDS and other ISR-related disorders.

Our studies have shown that ISRIB is effective in ameliorating the chondrodysplastic defects by treatment in the fetal and postnatal periods where the growth plate is most active as rapid growth occurs. We did not test if ISRIB treatment would be able to reverse the dwarfism, if given after maturity and cessation of skeletal growth. It should be noted, however, that the expression of 13del transgene reduces postnatally around 3 weeks and stops expressing in HCs at around 4 weeks ([@bib107]). We previously showed that postnatally, the intensity of ER stress signalling correlates with levels of 13del expression ([@bib107]). This would mean that in a scenario where the ER stress is relieved, treating adult 13del mice with ISRIB may not be effective in overcoming the dwarfism. Therefore, prevention of aberrant HC differentiation during the growth phase should be more effective therapeutically than once growth has ceased in maturity.

Our study has implications for other disorders. ER stress and the ISR are also implicated in intervertebral disc degeneration, which is very common in humans, and a major cause of low back pain ([@bib117]; [@bib123]). Therefore, an important question arising is whether activation of the ISR and its associated ectopic expression of ATF4 and its downstream targets such as *Sox9* may underlie common skeletal diseases such as intervertebral disc degeneration and osteoarthritis.

The direct activation of *Sox9* by ATF4, also may have broad implications for other diseases. SOX9 is a potent transcription factor with critical roles in cell fate determination, not only in chondrocytes but also in many different cell types, notably stem cells (dermal papilla, gonads, intestinal and neural, etc.)([@bib86]; [@bib87]) and is activated in other common and acquired diseases such as cancer and fibrosis ([@bib87]; [@bib4]). Ectopic expression of SOX9 has been widely reported to mediate ECM deposition, such as collagens and other structural proteins, in the pathology of fibrosis in multiple organs, including the liver ([@bib4]), kidney ([@bib48]; [@bib61]), lung and myocardium ([@bib55]). These observations of ectopic and/or over expression of SOX9 raise questions about the upstream role of the ISR in the pathogenesis and/or progression of these diseases. Also, SOX9 directly activates the ER stress transducer BBF2H7 ([@bib36]) with added implications for those diseases where ectopic or over-expression of SOX9 has been described ([@bib87]; [@bib4]; [@bib55]) Therefore, whether targeting eIF2a-mediated translation control could be a general therapeutic strategy for ISR-associated common human diseases is another important question that should be addressed in future.

Materials and methods {#s4}
=====================

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\           Designation              Source or reference                                   Identifiers                Additional information
  (species) or resource                                                                                                             
  ----------------------- ------------------------ ----------------------------------------------------- -------------------------- -------------------------------------
  Strain, strain\         *13del*                  PMID: 17298185                                                                   Maintained in F1\
  background\                                                                                                                       (C57BL/6 x CBA) background
  (*Mus musculus*)                                                                                                                  

  Strain, strain\         *C10-Atf4*               This paper                                                                       
  background\                                                                                                                       
  (*Mus musculus*)                                                                                                                  

  Strain, strain\         *Ddit3^-/-^*             PMID: 9531536                                                                    Gift from Prof. David\
  background\                                                                                                                       Ron's lab (University of\
  (*Mus musculus*)                                                                                                                  Cambridge, UK)

  Strain, strain\         *Fgf21^-/-^*             PMID:19589869                                                                    Gift from Prof. Nobuyuki\
  background\                                                                                                                       Itoh's lab (University\
  (*Mus musculus*)                                                                                                                  of Kyoto, Japan)

  Strain, strain\         *Col10a1^Egfp^*          PMID:25092332                                                                    
  background\                                                                                                                       
  (*Mus musculus*)                                                                                                                  

  Strain, strain\         *Sox9*^flox/flox^        PMID:12414734                                                                    Gift from Prof. Andreas\
  background\                                                                                                                       Schedl's lab (Institute of\
  (*Mus musculus*)                                                                                                                  Biology Valrose, France)

  Strain, strain\         *Col10a1^Cre^*           PMID:25092332                                                                    
  background\                                                                                                                       
  (*Mus musculus*)                                                                                                                  

  Cell line\              ATDC5                    RCB0565; PMID:8609176                                 Chisa Shukunami            
  (*Mus musculus*)                                                                                                                  

  Cell line\              MEF                      Isolated from\                                                                   Mouse Embryonic\
  (*Mus musculus*)                                 E13.5 mouse embryo (F1)                                                          Fibroblast

  Cell line\              NIH 3T3                  ATCC CRL-1658                                                                    Mouse fibroblast\
  (*Mus musculus*)                                                                                                                  suitable for transfection

  Transfected\            pSox9-2.7K               This paper                                                                       2.7K Sox9 promoter inserted\
  construct                                                                                                                         into pGL3 basic vector (Promega)

  Transfected\            pSox9-1.8K               This paper                                                                       1.8K Sox9 promoter inserted\
  construct                                                                                                                         into pGL3 basic vector (Promega)

  Transfected\            pSox9-0.8K               This paper                                                                       0.8K Sox9 promoter inserted\
  construct                                                                                                                         into pGL3 basic vector (Promega)

  Transfected\            pSox9-1.8M1              This paper                                                                       1.8K Sox9 promoter with one\
  construct                                                                                                                         mutated ATF4 binding site\
                                                                                                                                    inserted into pGL3 basic vector\
                                                                                                                                    (Promega)

  Transfected\            pSox9-1.8M2              This paper                                                                       1.8K Sox9 promoter with one\
  construct                                                                                                                         mutated ATF4 binding site\
                                                                                                                                    inserted into pGL3 basic\
                                                                                                                                    vector (Promega)

  Transfected\            pSox9-1.8M3              This paper                                                                       1.8K Sox9 promoter with two\
  construct                                                                                                                         mutated ATF4 binding sites\
                                                                                                                                    inserted into pGL3 basic\
                                                                                                                                    vector (Promega)

  Transfected\            pFgf21-Luc1              This paper                                                                       2K Fgf21 promoter inserted\
  construct                                                                                                                         into pGL3 basic vector (Promega)

  Transfected\            pFgf21-Luc2              This paper                                                                       1.2K Fgf21 promoter inserted\
  construct                                                                                                                         into pGL3 basic vector (Promega)

  Transfected\            pFgf21-Luc3              This paper                                                                       0.8K Fgf21 promoter inserted\
  construct                                                                                                                         into pGL3 basic vector (Promega)

  Transfected\            pFgf21-Luc4              This paper                                                                       0.4K Fgf21 promoter inserted\
  construct                                                                                                                         into pGL3 basic vector (Promega)

  Transfected\            pFgf21-M1                This paper                                                                       1.2K Fgf21 promoter with one\
  construct                                                                                                                         mutated ATF4 binding site inserted\
                                                                                                                                    into pGL3 basic vector (Promega)

  Transfected\            pFgf21-M2                This paper                                                                       1.2K Fgf21 promoter with one\
  construct                                                                                                                         mutated ATF4 binding site inserted\
                                                                                                                                    into pGL3 basic vector (Promega)

  Transfected\            pFgf21-M3                This paper                                                                       1.2K Fgf21 promoter with two\
  construct                                                                                                                         mutated ATF4 binding site\
                                                                                                                                    inserted into pGL3 basic vector\
                                                                                                                                    (Promega)

  Antibody                anti-ATF4                sc-200                                                Santa Cruz                 rabbit IgG

  Antibody                anti-CHOP                sc-575                                                Santa Cruz                 rabbit IgG

  Antibody                anti-SOX9                AB5535                                                Millipore                  rabbit IgG

  Antibody                anti-ATF3                HPA001562                                             Sigma                      rabbit IgG

  Antibody                anti-FGF21               42189                                                 AIS                        rabbit IgG

  Antibody                anti-PPP1R15A            sc-825                                                Santa Cruz                 rabbit IgG

  Antibody                anti-BiP                 ADI-SPA-826                                           ENZO                       rabbit IgG

  Antibody                anti-beta Actin          A2228                                                 Sigma                      mouse IgG

  Commercial\             In Situ Cell Death\      12156792910                                           Roche                      TUNEL assay
  assay or kit            Detection Kit                                                                                             

  Commercial\             Dual-Luciferase\         E1910                                                 Promega                    Luciferase assay
  assay or kit            Reporter Assay System                                                                                     

  Commercial\             BrdU staining kit        93--3943                                              Thermo Fisher Scientific   
  assay or kit                                                                                                                      

  Chemical\               ISRIB                    SML0843                                               Sigma                      
  compound, drug                                                                                                                    

  Software,\              RMA algorithm            R Bioconductor                                                                   Robust Multi-chip Average
  algorithm                                                                                                                         

  Software,\              *k*-Means Clustering\    DOI: <https://doi.org/10.1016/j.patrec.2009.09.011>                              
  algorithm               algorithm                                                                                                 

  Software,\              Gene Ontology database   PMID:10802651                                                                    
  algorithm                                                                                                                         

  Software,\              HOMER software package   PMID:20513432                                                                    
  algorithm                                                                                                                         

  Software,\              Bowtie program           PMID:19261174                                                                    
  algorithm                                                                                                                         

  Software,\              Picard toolkit of\       <https://tldrlegal.com/license/mit-license>           MIT                        
  algorithm               Broad Institute                                                                                           

  Software,\              Prism                                                                          GraphPad software          
  algorithm                                                                                                                         
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------

Genetically modified mice and mutant analysis {#s4-1}
---------------------------------------------

The 13del transgenic mice have been described previously ([@bib107]) and were maintained in F1 (C57BL/6 x CBA) background. The *Ddit3 (Chop)***-**null mice (gift of David Ron) and Fgf21-null mice were reported previously ([@bib124]; [@bib41]). The Sox9-flox mice were a gift from Andreas Schedl ([@bib1]). A BAC transgene vector (*Col10a1-Atf4-*IRES*-Egfp*, abbreviated as *C10-Atf4*) was generated using the BAC clone RPCI23-194I3 (113), which carries the *Col10a1* gene, and by inserting the coding region of *Atf4* at the *Col10a1* ATG codon in exon 2. Included in the transgene are 154 kb and 35 kb of 5′ and 3′ sequences, respectively, relative to *Col10a1* exons. This BAC vector can recapitulate the expression pattern of *Col10a1* ([@bib118]). *C10-Atf4* transgenic mice were generated by pronuclear injection into F1 C57/Bl6 x CBA zygotes and maintained in the same F1 background. The primers used for *C10-Atf4* mouse genotyping were listed in [Supplementary file 7](#supp7){ref-type="supplementary-material"}. Animal care and experiments performed were in accordance with the protocols approved by the Committee on the Use of Live Animals in Teaching and Research of the University of Hong Kong.

Comparisons of *13del* vs. *13del;Ddit3^-/^*^-^, *13del* vs. *13del;Sox9^c/c^*, *C10-Atf4* vs. *C10-Atf4;Sox9^c/c^* and *13del* vs. *13del; Fgf21^-/-^* were conducted between littermates only, in which any animal of desired genotype were only compared to its control littermates. For each compound mutant line, double or triple mice were intercrossed for \>10 generations before any evaluation to avoid issues of differences in genetic background. The gender of double or triple mutant test animals was randomized when sampling for analysis.

The *13del*, *Col10a1^cre^*, *Sox9^flox/flox^* and *Fgf21^-/-^* were genotyped according to previous studies ([@bib107]; [@bib118]; [@bib1]; [@bib41]), respectively.

RNA preparation and microarray analysis {#s4-2}
---------------------------------------

The fractionation methodology was established as described previously ([@bib104]). In brief, chondrocyte sub-populations in transverse sections of the proximal tibia of 10-day-old WT or 13del mouse were obtained by cryosectioning. 5-micron sections were prepared and pooled into fractions consisting of 10 sections per fraction to ensure separation of each cell type in the growth plate. Samples were dissolved in Trizol reagent (Invitrogen) for RNA extraction. To guide the sub-division of chondrocyte populations into zones, every 10th section was examined histologically and 10% of the RNA isolated from sections selected at regular intervals was used for the detection of known growth plate markers by RT-PCR analyses ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}).

Total RNA was extracted and hybridized to Mouse Genome 430 2.0 Gene Chip (Affymetrix). Gene expression data for each sample in triplicate were normalized using Robust Multi-chip Average (RMA) algorithm in *R* Bioconductor package. The *k*-Means Clustering algorithm([@bib88]; [@bib44]) was used to identify the distinct expression patterns of genes in WT and 13del growth plates, which aims to partition *n* observations into *k* clusters in which each observation belongs to the cluster with the nearest mean, serving as a prototype of the cluster. The Gene Ontology analysis was performed for each cluster of genes by using the Gene Ontology database ([@bib3]) and the David Web Tools ([@bib16]).

HOMER motif discovery {#s4-3}
---------------------

The DNA-binding motif enrichment analysis was performed by using HOMER software package ([@bib35]). The DNA sequences flanking the genes' transcription start sites 2 kb up- and downstream were extracted from the mouse reference genome assembly (mm9). The HOMER, the TRANSFAC ([@bib114]) and the ISMARA ([@bib5]) transcription factor databases were integrated to create the TF binding motif library for screening. The DNA sequences of the interrogated gene sets were compared with those extracted from the remainder gene sets to identify the differentially enriched DNA binding motifs and the TFs.

ChIP-sequencing data analysis {#s4-4}
-----------------------------

The ATF4 and CHOP ChIP-sequencing datasets ([@bib27]) were downloaded from the GEO database (GSE35681). The DNA sequences were aligned to the mm9 mouse reference genome assembly with Bowtie program ([@bib56]). The analysis of coverage signal intensity and peak detection were performed by using Picard toolkit of Broad Institute (MIT) (<https://tldrlegal.com/license/mit-license>). The binding peaks located within 10 kb up or downstream of the TSS in each target gene were identified for statistical analysis in each cluster.

Histological and immunofluorescence analyses {#s4-5}
--------------------------------------------

Methods used were as described previously ([@bib107]). In brief, limbs were fixed in 4% PFA, followed by demineralization in 0.5M EDTA (pH 8.0) before embedding in paraffin. Slides were stained with Alcian Blue for cartilage matrix and Fast Red for nuclei. Immunofluorescence was performed using antibodies against ATF4 (sc-200, Santa Cruz), ATF3 (HPA001562, Sigma), CHOP (sc-575, Santa Cruz), PPP1R15A (sc-825, Santa Cruz), FGF21 (42189, AIS) and Sox9 (AB5535, Millipore).

FAST staining {#s4-6}
-------------

FAST staining referred to a multidye staining procedure using fast green, Alcian blue, Safranin-O, and tartrazine and was performed as described previously([@bib59]).

In-situ hybridization {#s4-7}
---------------------

In-situ hybridization was performed as previously described([@bib108]), using \[^35^S\]UTP-labeled ribopobes for *Col10a1, Col2a1, Hspa5 (Bip), 13del*([@bib107]), *Ihh* (from A. McMahon), *Sox9*([@bib73]) and the *PTHrP* receptor (*Ppr)* (from H. Kronenberg). The probes for *Atf4, Atf3, Ddit3 (Chop), Ero1l* and *Fgf21* were mouse cDNA fragments, generated by RT-PCR from growth plate total RNA. The primers used for probe synthesis were listed in [Supplementary file 7](#supp7){ref-type="supplementary-material"}.

Generation of *13del;Col10a1^Egfp^*Egfp*13 del;Fgf21^-/-^* chimeras {#s4-8}
-------------------------------------------------------------------

We utilized compound mutants carrying the 13del transgene and a *Col10a1^Egfp^* allele \[*Egfp* knocked into the *Col10a1* gene ([@bib118]) so that all 13del HCs are marked by EGFP expression. We created mouse chimeras by aggregating morulae from *13del;Col10a1^Egfp^* and *13del;Fgf21^-/-^*mice. The chimeras (agouti/black) generated were genotyped for the different alleles by PCR. The HCs from *13del;Col10a1^Egfp^* with FGF21 expression were visualized by EGFP or by immunostaining for EGFP on cryosectioned growth plates.

TUNEL assay and BrdU incorporation {#s4-9}
----------------------------------

Methods used are as described in [@bib107]. In brief, apoptotic cells in the growth plate of examined animals were detected by in situ terminal deoxynucleotidyltransferase deoxyuridine triphosphate nick end labeling (TUNEL) assay using the In Situ Cell Death Detection Kit (Roche) following the manufacturer's instructions. Cell proliferation activity was analyzed using BrdU labeling assay. Mice were injected intraperitoneally with 200 μg of BrdU per gram of body weight two hours before sacrifice. Following fixation, BrdU in paraffin sections was detected using a BrdU Staining Kit (93--3943, Thermo Fisher).

Chromatin immunoprecipitation (ChIP) assay {#s4-10}
------------------------------------------

The protocol used for ChIP was adapted from the instructions of ChIP Assay Kit (Millipore). Cultured cells or limbs dissected from E15.5 WT and *C10-Atf4* embryos were homogenized and crosslinked. DNA was sonicated and immunoprecipitated with rabbit anti-ATF4 (sc-200, Santa Cruz Biotechnology) or rabbit anti-CHOP (sc-575, Santa Cruz Biotechnology) antibody. The pull-down DNA was purified and analyzed by PCR.

Protein extraction and immunoblot analysis {#s4-11}
------------------------------------------

Cartilages isolated from the mice were pulverized in liquid nitrogen and then lysed with RIPA buffer. The lysate was subjected to SDS-PAGE under reducing conditions and probed with FGF21 and beta-actin antibody. For drug-treated animals, the proximal part of the tibia was embedded in RIPA buffer for cryosection. Transverse sections (5 μm thick) were cut and pooled into fractions consisting of 10 sections per fraction to ensure separation of each cell type in the growth plates before further lysed in RIPA. The lysate was subjected to SDS-PAGE under reducing conditions and probed with ATF4, BiP (ADI-SPA-826, Enzo) and beta-actin (A2228, Sigma) antibody.

Dual-luciferase reporter assay {#s4-12}
------------------------------

Luciferase assays were conducted using a dual luciferase reporter assay kit (Promega), according to the manufacturer's protocol. Different promoter fragments of *Sox9* or *Fgf21* were cloned into a pGL3-basic vector (Promega) to drive the expression of firefly luciferase. ATDC5 (RCB0565, RIKEN, Wako, Japan) or NIH3T3 cells (ATCC CRL-1658) were plated at 2 × 10^4^ cells/well in 24-well plates. After 18 hr incubation, the cells were transfected with tested constructs with *Renilla* luciferase vector, which served as an internal control. Data presented are ratios of Luc/Renilla activity from at least three different experiments, and each experiment was performed in triplicate for each DNA sample.

Quantitative PCR {#s4-13}
----------------

Quantitative PCR was performed using SYBR-Green master mixture according to the manufacturer\'s instruction (Takara). Appropriate amounts of cDNA (or DNA) and primers were mixed with distilled water up to 10 μl and combined with an equal amount of SYBR-Green master mixture. The reaction was run on the StepOne Real-Time PCR system (Applied Biosystems, A and B). The Ct (cycle threshold) is defined as the cycle number required for the fluorescent signal to cross the threshold. The relative expression levels of target genes are calculated by normalizing to the expression level of GAPDH using delta-delta-Ct (Relative expression level = 2\^ - (Ct~target~- Ct~Gapdh~)). The melting curve was also measured to detect the specificity of the primers. The primers used for qRT-PCR were listed in [Supplementary file 7](#supp7){ref-type="supplementary-material"}.

ISRIB treatments {#s4-14}
----------------

ISRIB (SML0843, Sigma) was dissolved in DMSO to make a 5 mg/ml stock and stored at 4-degree. Animals were intraperitoneally injected with ISRIB ([@bib19]; [@bib98]) (2.5 mg/kg, freshly diluted in 0.9% saline) or vehicle (5% DMSO in saline) from E13.5 till p20 stage or from p0 till 4-week stage. The animals were collected at p10 and p20 stages for further analysis.

Radiography of mouse skeleton {#s4-15}
-----------------------------

Mice were anesthetized before radiography using digital Faxitron system (UltraFocus) at 20kVA for 5 s exposure.

Statistical analyses {#s4-16}
--------------------

No statistical methods were used to predetermine sample size. Statistical methods used are detailed in the figure legends. We used two-tailed Mann-Whitney *U*-test to establish statistical significance in all mouse phenotypic analysis, unpaired Two-tailed Student's *t*-test in the luciferase assay, and one-way ANOVA in the ISRIB-treatment studies, p\<0.05 was considered statistically significant.

Data availability {#s4-17}
-----------------

All primary microarray data are deposited into Gene Expression Omnibus (GEO) website (Accession Number GSE99306). Source Data for all figures are provided with the paper and supplementary files.
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###### Enriched motifs identified in cluster I genes using HOMER software package.

(Related to [Figure 1](#fig1){ref-type="fig"})
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###### List of ATF4 and CHOP target genes in each cluster.

Genes containing ATF4 and CHOP binding peaks within 10 kb from TSS were listed. (Related to [Figure 1](#fig1){ref-type="fig"})
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###### Primers used for genotyping, probe synthesis and qRP-PCR.

(Related to Materials and methods)
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Data availability {#s7}
-----------------

All primary microarray data are deposited into Gene Expression Omnibus (GEO) website (accession no. GSE99306).

The following dataset was generated:

TanZWang CNiu B2017Expression data of chondrocytes subpopulations from WT, 13del and 13del:Chop-/- mice at P10 stage<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE99306>Publicly available at the NCBI Gene Expression Omnibus (accession no: GSE99306)

The following previously published dataset was used:

Kaufman RJHan JSartor MA2013ChIP-seq and mRNA-seq experiment to find the direct target genes of ATF4 and CHOP<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE35681>Publicly available at the NCBI Gene Expression Omnibus (accession no: GSE35681)
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Inhibiting the Integrated Stress Response Prevents Aberrant Chondrocyte Differentiation, alleviating Chondrodysplasia\" for consideration by *eLife*. Your article has been reviewed by four peer reviewers, including Clifford J Rosen as the Reviewing Editor and Reviewer \#1, and the evaluation has been overseen by Harry Dietz as the Senior Editor.

The reviewers have discussed the reviews with one another and the Reviewing Editor (BRE) has drafted this decision to help you prepare a revised submission.

Summary:

There was general enthusiasm for this manuscript from all four reviewers. It breaks new ground in understanding the reversion of chondrocyte hypertrophy via the PERK pathways and enhanced secretion of ATF4 and CHOP and transactivation of *Sox9*. However, there were concerns that need to be addressed in the full revision as noted below:

Essential revisions:

1\) Clarify whether FGF-21 works in a cell autonomous or non-cell autonomous manner on chondrocytes and whether there is a phenotype in the *Fgf21^-/-^*mice.

2\) Redo the statistics using ANOVA rather than t- tests, which are not appropriate.

3\) Specify the selectivity of ISRIB and how it was solubilized; also address whether the authors used it in older mice at skeletal maturity.

4\) Clarify mouse backgrounds, sex, numbers and age.

Reviewer \#1:

In this paper, Wang and colleagues exploited a mouse model of Metaphyseal Chondrodysplasia type Schmid (MCDS) to examine provide the impact of the (Integrated Stress Response) ISR on cell fate. They showed the protein kinase RNA-like ER kinase (PERK) pathway that mediated preferential synthesis of ATF4 and CHOP, dominated the mechanism of dysplasia by reverting chondrocyte differentiation via ATF4 directed transactivation of *Sox9*. Chondrocyte survival is enabled by CHOP, often considered a death promoter, and transactivation of *Fgf21* by the dual action of CHOP and ATF4. Treatment of mutant mice with a chemical inhibitor of PERK signaling prevented the differentiation defects and ameliorated chondrodysplasia. The authors concluded that inhibition of the ISR could become the cornerstone of a rationale therapeutic strategy for stress-induced skeletal disorders.

Overall the paper is well written, the methods are clearly spelled out and the genetic studies are well described and logical. The mechanisms of the integrated stress response are complex, but the authors have systematically approached this by using network and pathways analysis to identify downstream pathways related to PERK, particularly ATF4 and CHOP to induce de-differentiation but excluding XBP1 in the UPR. The mouse model of 13del MCDS provides a useful model of misfolded mutant collagen X inducing an ER stress suggesting its primary role in the pathogenesis of the mutation. Their data that increases in ATF4 and CHOP through FGF21 contribute to the de-differentiation phenotype are relatively compelling; loss of function and gain of function studies provide further support for their central tenet. However, there are a few concerns:

Of major importance there is no sex mentioned for the mice; the mouse numbers are small (n=5) and the mouse backgrounds are quite different. All this may contribute to some phenotypic differences; The Chop^-/-^ mice are either 129 or CD1 mixed backgrounds, crossed with the 13del which are B6xCBA F1 hybrids; and then the crosses with *Fgf21^-/-^* that are on a B6 background. And there are no data on the *C10-Atf4* Tg. So much more explanation of the crosses is required and how the mixed background that result from these crosses could contribute to the growth plate phenotypes.

FGF21 plays a critical role in the mutational phenotype in respect to survival; it would be useful to show the absence of a growth plate phenotype in the FGF21 null mice. Also, for Figure 6D qRT-PCR should be shown rather than the relative expression by micro array.

It's not clear from the figure if in the 13del mice only *Sox9* is upregulated; particularly relevant would be changes in Gli 2,3 which have promoter sites for binding by ATF4; moreover, were the gene expression changes checked by qRT-PCR or only by micro array; that needs clarification in the legend.

How specific is ISRIB as an inhibitor of the Integrated stress response?

Also, the rescue of 13del wit ISRIB was not complete and as noted there was still mutant collagen X present. Can the authors provide some insight into other potential mechanisms for the incomplete skeletal rescue if indeed the major pathway is through PERK?

The body length phenotype is of interest in the *C10-Atf4* Tg; is it due to increases in vertebrae growth plate; intervetebral discs? Can the authors elaborate on that phenotype.

Reviewer \#2:

I am very supportive of this study, but feel some minor revisions would improve the manuscript.

This study addresses the role of eIF2α phosphorylation and its downstream effects in the pathogenesis of chondrodysplasia caused by a 13 bp deletion within the *Col10a1* gene. The authors identify the unfolded protein response to be induced in bone growth plates from mutant mice; ectopic expression of ATF4 is then shown to phenocopy some features of the chondrodysplasia by driving loss of chondorcyte differentiation; and haploinsufficiency for *Sox9* (a target of ATF4) is shown to rescue the bone defects cause by mutant *Col10a1* or over-expression of ATF4. In contrast, loss of Chop (another ATF4 target) is shown to exacerbate the bone growth defect. Induction of FGF21 by ATF4 and CHOP is shown to promote the survival of hypertrophic chondrocytes expressing mutant *Col10a1*. The eIF2B-activating drug ISRIB is then used to rescue much of the bone phenotype of *Col10a1* mutant mice. Finally, evidence is presented suggesting ISRIB reduces signalling downstream of eIF2α phosphorylation.

This is a substantial piece of work comprising many well-conducted experiments. It will be of interest to researchers in the fields of the integrated stress response and of bone development. The beneficial effects of CHOP on chondrocyte survival are especially interesting since they chime with previous studies (see below).

1\) Some of the experiments are presented as single examples (Figure 2A and E, Figure 3A and C, Figure 6A-D, Figure 8) albeit sometimes at multiple time points. Are repeats available and, if so, can the reproducibility of these effects be displayed in a quantitative form with statistical analysis? This is especially relevant to Figure 8B where the data quality is less good than elsewhere in this manuscript.

2\) Could the authors comment on any solubility issues with ISRIB that may have impacted its bioavailability? This drug is somewhat notorious for its difficulty to dissolve in biologically compatible solutions.

3\) The wording \"ATF4 was also insignificantly lowered\" subsection "The PERK-p-eIF2α signaling pathway is downregulated explicitly by treatment of ISRIB" should probably be changed if the statistical test showed no difference. There is no need for Atf4 mRNA to be affected since the effects of ISRIB would be on ATF4 translation rather than transcription.

4\) I am not convinced that Student\'s t-tests, which are used frequently herein, are always appropriately used. Statistical advice ought to be sought, and at the very least adjustments made for multiple comparisons. Analysis of variance with a subsequent post-hoc test would seem more appropriate to this reviewer. This is especially true for Figure 8 but is relevant in several other experiments where t-tests alone appear to have been employed.

Reviewer \#3:

In this study, the authors have further examined the pathogenesis of Metaphyseal Chondrodysplasia type Schmid (MCDS), using the 13del mouse model. The mutant mice carry a 13 bp deletion in *Col10a1* and mimic the human condition genetically and phenotypically, including intracellular accumulation of misfolded Col X that leads to ER stress, growth plate chondrocyte malfunction and skeletal growth retardation. Using a combination of transcriptome, biochemical and transgenic approaches, the authors found that the protein kinase RNA-like ER kinase (PERK) pathway -a component of the integrated stress response (ISR)- was activated in mutant growth plates and was associated with increased expression of ATF4 and CHOP. Aberrant ATF4 production likely caused broad and excessive *Sox9* expression, delaying growth plate chondrocyte maturation and hypertrophy, causing chondrocyte accumulation and growth plate lengthening, and impairing endochondral ossification and skeletal growth. Indeed, conditional ablation of *Sox9* using ColX-cre mice ameliorated the skeletal and growth plate phenotype of the 13del mice. The authors tested a pharmacological ISR inhibitor that blocks the action of phosphorylated eIF2α and found that systemic drug administration ameliorated the growth plate and skeletal phenotype of juvenile 13del mice. The authors conclude that pharmacological inhibition of the ISR may represent a rational therapeutic strategy for stress-related skeletal conditions.

The study is of significant interest since the pathogenesis of MCDS and related pathologies remains poorly understood. The study describes a very large and impressive body of experimental studies and provides several lines of evidence that the aberrant behavior of growth plate chondrocytes in the 13del mice is due to excessive and lingering expression of *Sox9*, a key transcription factor that is normally tightly regulated to permit growth plate chondrocyte maturation and a seamless transition from hypertrophic cartilage to endochondral bone. Providing evidence that a pharmacological agent targeting ISR elicits beneficial effects on skeletal growth in the mutants adds significant translational medicine value and relevance to the study.

Concerns are minor.

The authors should provide details of how the growth plate chondrocytes were fractionated into 3 or 4 subpopulations before their use in the transcriptome analyses. Because the data are used to reach mechanistic implications, it is important to show that each fraction was in fact composed by a distinct subpopulation. This is particularly important for 13del samples; given that the mutant growth plates contained abnormal distribution of *Sox9-, col2*- and *Ihh*-expressing cells, the cells may have been more difficult to separate into distinct subpopulations if they had intermediate cell phenotypes (volume, shape, etc.).

The data on FGF21 are of particular interest. *Fgf21* was found to be the most up-regulated gene in 13del hypertrophic chondrocytes, and *Fgf21* deletion in 13del mice led to increased apoptosis in the hypertrophic zone. The authors suggest that the excess levels of FGF21 protected the 13del mutant chondrocytes from apoptosis. Do the authors have data on how such protection occurred and whether the fate of hypertrophic cells was altered in the compound mutant mice, including possible consequences on primary spongiosa? Based on data presented, it appears that FGF21 has no role in WT growth plates. Could the authors comment on this?

The apparent beneficial effects of the ISR inhibitor on the 13del skeletal phenotype are promising, but appear to be modest. Also, only juvenile mice (up to p20) were examined. Did the authors try different drug regimens or administration routes to improve efficacy? Could beneficial effects be elicited in older mice up to skeletal maturity around 2-3 months of age? If treatment was stopped at P20 and mutant mice were followed over time, what happened to their skeletal phenotype?

Reviewer \#4:

This study uses a mouse model of Metaphyseal Chondrodysplasia type Schmid (MCDS) to investigate how the integrated stress response affects chondrocyte cell differentiation. This is a comprehensive and insightful study that begins to address the molecular and cellular mechanisms by which 13del mutation in *Col10a1* causes skeletal dwarfism. The authors identify protein kinase RNA-like ER kinase (PERK) as a molecule that regulates ATF4 and CHOP to regulate chondrocyte differentiation and survival. The authors show that activation of the unfolded protein response leads to expression of ATF4 and activation of *Sox9* expression, which represses chondrocyte differentiation. They also show that ATF4 and CHOP promote chondrocyte survival by activating FGF21 and that FGF21 is necessary for cell survival. Finally, they show that a small molecule inhibitor, ISRIB, reduces the dwarfism phenotype of 13del mice.

When Atf4 is overexpressed, Col10a1 expression is greatly decreased. How is the HC zone actually defined in this model? Why is *C10-Atf4* not itself downregulated?

If chondrocytes have impaired differentiation, does this mean that they retain features of proliferating or prehypertrophic chondrocytes? Does chondrocyte proliferation extend into this undifferentiated and expanded HC zone?

The expression of *Sox9* could be quantified in Figure 5C. Is expression per cell changed or just number of cells?

Figure 6D does not make sense. The text says 40% decrease in *Fgf21* in 13del; CHOP^-/-^ mice; however, the red line is above the green line in the figure?

The potential role of FGF21 in cell survival is interesting; however, given the long range signaling abilities of FGF21, it should be shown whether FGF21 is acting locally on HCs or indirectly through another factor and non HC tissue. Is beta-klotho expression changed in HCs and is *FGFR1* responsible for supporting cell survival in 13del HCs? Given that *Fgf21* was highly increased, could it have effects other that mediating the ISR? Does FGF21 regulate growth hormone signaling through STAT5, IGF-1, or IGF-1 binding protein (see PMC2575072, PMC3406689).

Although probably beyond the scope of this study, it may be interesting to see how the 13del mouse responds to FGF21 treatment at the growth plate. Is there a direct effect on ERK phosphorylation?

Figure 8B Blot is of low quality. The actin bands are not consistent. This could explain the differences seen between UHC and LHC. Quantification of this expression data would help especially for BIP.

Figure 9. It would be helpful to also indicate the suppressive effect of ISRIB on eIF2B and subsequently ATF4.

Figure 9---figure supplement 1D. Label indicates that TUNEL is Red, however the probe is Green. Change for consistency.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

Thank you for resubmitting your work entitled \"Inhibiting the Integrated Stress Response Prevents Aberrant Chondrocyte Differentiation, alleviating Chondrodysplasia\" for further consideration at *eLife*. Your revised article has been favorably evaluated by Harry Dietz (Senior Editor) and Clifford Rosen (Reviewing Editor).

The manuscript has been improved and the response to reviewers is complete except for the statistical analysis. This is the only remaining issue prior to acceptance and we ask that the authors more fully justify the use of the Mann-U Whitney test, particularly as it relates to multiple comparisons in Figure 8 vs the more standard and accepted one way or in some cases two way ANOVA. We recommend that you consult a statistician for your response. Once this is resubmitted, we can rapidly make a final decision.

10.7554/eLife.37673.039

Author response

> Essential revisions:
>
> 1\) Clarify whether FGF-21 works in a cell autonomous or non-cell autonomous manner on chondrocytes and whether there is a phenotype in the FGF-21-/- mice.

WT hypertrophic chondrocytes (HCs) do not express FGF21. In our paper we have shown that expression of *Fgf21* is activated as a consequence of ER stress in 13del HCs and this has a survival effect. To determine whether the pro-survival role of FGF21 was cell autonomous or non-cell autonomous in 13del hypertrophic chondrocytes (HCs), we tested the survival of 13del HCs carrying an *Fgf21* null mutation, in mouse chimeras. We utilised compound mutants carrying the 13del transgene and a *Col10a1^Egfp^* allele \[*Egfp* knocked into the *Col10a1* gene (Tsang et al., 2007)\] so that all 13del HCs are marked by GFP expression. We created mouse chimeras by aggregating *13del;Col10a1^Egfp^*and *13del;Fgf21^-/-^* morulae. In the ensuing chimeras, 13del HCs are marked by EGFP expression, and express *Fgf21*. Mice with different degrees of *13del;Col10a1^Egfp^:13del;Fgf21^-/-^* chimerism, were analysed for HC survival. We found that *13del;Fgf21^-/-^* HCsadjacent to *13del;Col10a1^EGFP^*HCs expressing FGF21 still underwent apoptosis. In Figure S9D-F, we also show that the differentiation defect in 13del HCs was unchanged in HCs unable to express *Fgf21* at p10, indicating the observed cell fate change was FGF21-independent. These results are described in subsection "ATF4 and CHOP mediate chondrocyte survival by activating *Fgf21"*.

This inability of *13del;Col10a1^Egfp^* to rescue *13del;Fgf21^-/-^* HCssuggests that FGF21 works in a cell autonomous manner to protect the cell from apoptosis (new Figure 7C-E). We further show that *Fgf21* null mice have normal growth plates and HC viability (Figure 7---figure supplement 1). These results are described in subsection "ATF4 and CHOP mediate chondrocyte survival by activating *Fgf21"*

> 2\) Redo the statistics using ANOVA rather than t- tests, which are not appropriate.

Thank you for the comment and advice. We have used Two-tailed Mann-Whitney *U*-test to test for statistical significance in all mouse phenotypic analyses. This is a nonparametric test of the null hypothesis that it is equally likely that a randomly selected value from one sample will be less than or greater than a randomly selected value from a second sample. Using this test, there is no change in outcome. We used Unpaired Two-tailed Student's *t*-test in the luciferase assay.

> 3\) Specify the selectivity of ISRIB and how it was solubilized; also address whether the authors used it in older mice at skeletal maturity.

The specific action of ISIRIB in targeting the translational control of p-eIF2α has been reported by different studies viz neurodegeneration (Dever et al., 1992; Harding et al., 2003), prostate cancer (Ron, 2002), memory enhancing (Wek, Jiang and Anthony, 2006; García, Meurs and Esteban, 2007), cognitive deficits after traumatic brain injury (Rzymski et al., 2010) and in rescuing of impaired sociability and anxiety-like behaviour (Ye et al., 2010). Biochemically, via a cell-base screen for inhibitors or PERK signaling, ISRIB (Integrated Stress Response Inhibitor) was identified as an effective inhibitor of ISR, that potently (IC~50~=5nM) reverses the effects of eIF2α phosphorylation (Wek, Jiang and Anthony, 2006).

In our paper we show ISRIB selectively functions as an inhibitor of ATF4 induction under ER-stress induced PERK signalling pathway (Figure 9). Consistent with the specific action on the PERK arm of the UPR, the ER stress induced degradation pathway mediated by IRE1, is not affected, as reflected by the unchanged expression level of XBP1^S^, as well as the persistent intracellular accumulation of 13del mutant protein.

In this study, the ISRIB was dissolved in DMSO to make a stock solution of 5mg/ml which was freshly diluted 10-fold with saline, for daily injection. We agree that the solubility of ISRIB has room for improvement, which may give a better therapeutic efficacy. In a recent prostate cancer study, we note that HPMT vehicle solution (0.5% w/v hydroxypropyl-methylcellulose dissolved in water plus 0.2% v/v Tween80, adjusted to pH 4) was used with favourable effect (Ron, 2002). This point has been discussed in the revised manuscript (Discussion section).

In our current study we have focused on using ISRIB to identify the upstream cause of the chondrocyte differentiation defect and also to test the utility of ISRIB in ameliorating or preventing the skeletal defect. We agree it would be interesting to know if treating mature MCDS mice with ISRIB could have utility in arresting or reversing the dwarfism but such study would take a long time and is outside the scope of our current study. It should be noted however that the 13del transgene reduces postnatally around 3 weeks and stops expressing in HCs at around 4-wk (Brostrom et al., 1996). We previously showed that the intensity of ER stress signalling correlates with levels of 13del expression (Brostrom et al., 1996). This would mean that in a scenario where the ER stress is relieved, such experiment on 13del mice may not be informative. Certainly, prevention of aberrant HC differentiation during the growth phase should be more effective therapeutically than once growth has ceased in maturity. This point has been discussed in the revised manuscript (Discussion section).

> 4\) Clarify mouse backgrounds, sex, numbers and age.

In this study, we compared 13del vs. *13del;Ddit3^-/-^*, 13del vs. *13del;Sox9^c/c^, C10-Atf4* vs. *C10-Atf4;Sox9^c/c^*and *13del* vs. *13del; Fgf21^-/-^*. These comparisons were conducted between littermates only, so that any animal of desired genotype is only compared to its control littermates Furthermore, for each compound double or triple mutant mice, we used mice that had been inbred for \>10 generation before any evaluation, to avoid genetic background issues. For clarification, we have described the genetic background and sampling methodology in the revised manuscript (subsection "Genetically modified mice and mutant analysis"). We did not observe any sex-associated phenotypic differences in MCDS, and the sex of test animals was randomized in this study. The number and age of test animals are now clarified in the corresponding figure legends.

> Reviewer \#1:
>
> \[...\] Of major importance there is no sex mentioned for the mice; the mouse numbers are small (n=5) and the mouse backgrounds are quite different. All this may contribute to some phenotypic differences; The Chop-/- mice are either 129 or CD1 mixed backgrounds, crossed with the 13del which are B6xCBA F1 hybrids; and then the crosses with FGF21 -/- that are on a B6 background. And there are no data on the *C10-Atf4* Tg. So much more explanation of the crosses is required and how the mixed background that result from these crosses could contribute to the growth plate phenotypes.

Please see our response to Essential Revision \#4. The impact of mouse background has been minimized and the sex of test animals was randomized, given the fact that no sex-associated phenotypic changes were observed in MCDS.

> FGF21 plays a critical role in the mutational phenotype in respect to survival; It would be useful to show the absence of a growth plate phenotype in the FGF21 null mice. Also, for Figure 6D qRT-PCR should be shown rather than the relative expression by micro array.

As described in our response to Essential Revision \#1 above, we have included the analysis of *Fgf21^-/-^* growth plates in Figure 7---figure supplement 1B and C. We observed no significant changes in histology or frequency of cell death in the *Fgf21* null growth plates.

We show the microarray data as it was from analyses of the data that we first noted that *Fgf21* expression was turned on in 13del HCs, and it is not expressed in WT HCs. This finding has been validated both by in situ hybridization, Western blot and immunohistochemistry (Figure 6). Therefore, we have not performed qRT-PCR analyses especially because not all 13del-HCs expressed *Fgf21* and measurements of absolute RNA levels in a bulk RNA scenario may not truly reflect levels of expression per cell.

> It's not clear from the figure if in the 13del mice only Sox 9 is upregulated; particularly relevant would be changes in Gli 2,3 which have promoter sites for binding by ATF4; moreover, were the gene expression changes checked by qRT-PCR or only by micro array; that needs clarification in the legend.

We have examined the microarray data and show the expression trend of GLIs in 13del in Figure 3---figure supplement 1A. No significant upregulation of *Gli2* or Gli3 was observed in 13del-LHCs. In the revised manuscript, we have validated this observation using qRT-PCR (Figure 3---figure supplement 1B) and elaborated on this point in the revised main text (subsection "ATF4 reprograms chondrocyte hypertrophy by directly activating *Sox9"*) and figure legend.

> How specific is ISRIB as an inhibitor of the Integrated stress response?
>
> Also, the rescue of 13del wit ISRIB was not complete and as noted there was still mutant collagen X present. Can the authors provide some insight into other potential mechanisms for the incomplete skeletal rescue if indeed the major pathway is through PERK?

As described in our response above, the specificity of ISIRIB, as an inhibitor of ISR has been previously reported by different studies.

As discussed in the manuscript, the incomplete rescue could be caused not only by the incomplete clearance of intracellular mutant collagen X, but also by limited bioavailability of ISRIB because of its poor solubility in biologically compatible solution as pointed out by reviewer 2. In our study, the expression level of ATF4 after treatment was lowered but was still detectable, the rescue therefore was incomplete. To improve the efficacy of ISRIB, the HPMT vehicle solution (as discussed in response to comment 3) could be tested in future studies. We thank the reviewer for the comment and have further elaborated on all these points in the revised Discussion section.

> The body length phenotype is of interest in the *C10-Atf4* Tg; is it due to increases in vertebrae growth plate; intervetebral discs? Can the authors elaborate on that phenotype.

Thank you for the question. The drawfism of *C10-Atf4* is correlated with the abnormalities in the growth plates of both the appendicular and axial skeleton (subsection "ATF4 expression in hypertrophic chondrocytes reprogrammes differentiation"). To illustrate this point, we have included histological analysis of *C10-Atf4* vertebrae in Figure 2---figure supplement 1C and D.

> Reviewer \#2:
>
> \[...\] 1) Some of the experiments are presented as single examples (Figure 2A and E, Figure 3A and C, Figure 6A-D, Figure 8) albeit sometimes at multiple time points. Are repeats available and, if so, can the reproducibility of these effects be displayed in a quantitative form with statistical analysis? This is especially relevant to Figure 8B where the data quality is less good than elsewhere in this manuscript.

Thank you for the comment. All these experiments were biologically repeated (n=3 or 5) and the representative figures were shown. Also, we have repeated the experiment in Figure 8B, and better images were presented in new Figure 9B.

> 2\) Could the authors comment on any solubility issues with ISRIB that may have impacted its bioavailability? This drug is somewhat notorious for its difficulty to dissolve in biologically compatible solutions.

As discussed previously, the poor solubility of ISRIB might impact its in vivo bioavailability, since the expression level of ATF4 after treatment was lowered but still detectable in ISRIB-treated HCs, the rescue therefore was incomplete. Thank you for the comment. We have further elaborated all these points in revised Discussion section.

> 3\) The wording \"ATF4 was also insignificantly lowered subsection "The PERK-p-eIF2α signalling pathway is downregulated explicitly by treatment of ISRIB" should probably be changed if the statistical test showed no difference. There is no need for Atf4 mRNA to be affected since the effects of ISRIB would be on ATF4 translation rather than transcription.

Thank you for the comment. We've rephrased the sentence (subsection "The PERK-p-eIF2α signalling pathway is downregulated explicitly by treatment of ISRIB").

> 4\) I am not convinced that Student\'s t-tests, which are used frequently herein, are always appropriately used. Statistical advice ought to be sought, and at the very least adjustments made for multiple comparisons. Analysis of variance with a subsequent post-hoc test would seem more appropriate to this reviewer. This is especially true for Figure 8 but is relevant in several other experiments where t-tests alone appear to have been employed.

Thank you for the comment and advice. We have used Two-tailed Mann-Whitney *U-*test to test for statistical significance in all mouse phenotypic analyses and Unpaired Two-tailed Student's *t*-test in the luciferase assay. Also, we have repeated the Western blot experiment in old Figure 8B, and better images are presented in new Figure 9B.

> Reviewer \#3:
>
> \[...\] The authors should provide details of how the growth plate chondrocytes were fractionated into 3 or 4 subpopulations before their use in the transcriptome analyses. Because the data are used to reach mechanistic implications, it is important to show that each fraction was in fact composed by a distinct subpopulation. This is particularly important for 13del samples; given that the mutant growth plates contained abnormal distribution of Sox9-, col2- and Ihh-expressing cells, the cells may have been more difficult to separate into distinct subpopulations if they had intermediate cell phenotypes (volume, shape, etc.).

Thank you for the comment. The fractionation methodology is described in our recent paper (Tan et al., 2018), and is now elaborated on in the revised Materials and methods section as below: In brief, chondrocyte sub-populations in transverse sections of the proximal tibia of 10-day-old WT or 13del mouse were obtained by cryosectioning. 5-micron sections were prepared and pooled into fractions consisting of 10 sections per fraction to ensure separation of each cell type in the growth plate. Samples were dissolved in Trizol reagent (Invitrogen) for RNA extraction. To guide the subdivision of chondrocyte populations into zones, every 10th section was examined histologically and 10% of the RNA isolated from sections selected at regular intervals was used for the detection of known growth plate markers by RT-PCR analyses (Figure 1---figure supplement 1B).

> The data on FGF21 are of particular interest. Fgf21 was found to be the most up-regulated gene in 13del hypertrophic chondrocytes, and Fgf21 deletion in 13del mice led to increased apoptosis in the hypertrophic zone. The authors suggest that the excess levels of FGF21 protected the 13del mutant chondrocytes from apoptosis. Do the authors have data on how such protection occurred and whether the fate of hypertrophic cells was altered in the compound mutant mice, including possible consequences on primary spongiosa? Based on data presented, it appears that FGF21 has no role in WT growth plates. Could the authors comment on this?

Please refer to our detailed response to Essential Revision \#1.

> The apparent beneficial effects of the ISR inhibitor on the 13del skeletal phenotype are promising, but appear to be modest. Also, only juvenile mice (up to p20) were examined. Did the authors try different drug regimens or administration routes to improve efficacy? Could beneficial effects be elicited in older mice up to skeletal maturity around 2-3 months of age? If treatment was stopped at P20 and mutant mice were followed over time, what happened to their skeletal phenotype?

Thank you for raising up these critical points for optimizing the preclinical study of ISRIB in MCDS treatment, which are also our current research goals. The mice at different stages will be studied and followed-up for different time periods. Please note our response in Essential Revision \#3 above to improve the vivo bioavailability of ISRIB and testing ISRIB in older mice. Please note that 13del transgene expression is greatly diminished at around 4 weeks. However by that age the dwarfism is well established and the 13del mice remain dwarfed. This is consistent with a permanent impact of the ER stress during the developmental period and the phase of rapid postnatal growth mediated by the growth plate. Therefore after growth slows, the level of ER stress should be reduced and one would not expect any further change. This point has been discussed in the revised manuscript (Discussion section).

> Reviewer \#4: \[...\] When Atf4 is overexpressed, Col10a1 expression is greatly decreased. How is the HC zone actually defined in this model? Why is *C10-Atf4* not itself downregulated?

*C10-Atf4* is a BAC transgene in which *Atf4* is inserted into *Col10a1* but is controlled by the regulatory elements of the *Col10a1* gene. We have shown that the BAC transgene recapitulates the HC specificity of expression. However, *Col10-Atf4* was not downregulated probably because the transgene may have integrated into a transcriptionally active site and could be in multiple copies, hence the expression of ATF4 is robust. However, in these transgenic mice the expression level of the endogenous *Col10a1* gene (diagnostic of the HC identity) is decreased in *C10-Atf4* mice because this is a reflection of the abnormal hypertrophic chondrocyte differentiation caused by ATF4 over-expression. However, since its expression was not totally abolished, we used this to help us to define the HZ.

> If chondrocytes have impaired differentiation, does this mean that they retain features of proliferating or prehypertrophic chondrocytes? Does chondrocyte proliferation extend into this undifferentiated and expanded HC zone?

Thank you for the comment. We have performed BrdU labelling analysis on *C10-Atf4* mice (two hours before sacrifice) and observed that these *C10-Atf4* HCs were BrdU-negative (Figure 2---figure supplement 1F) (subsection "ATF4 reprograms chondrocyte hypertrophy by directly activating *Sox9"*). Given the fact that these cells express the pHC markers, such as *Sox9, Ihh* and *Ppr*, we conclude that these cells are prehypertrophic-like chondrocytes.

> The expression of Sox9 could be quantified in Figure 5C. Is expression per cell changed or just number of cells?

The expression of *Sox9*, and its downstream target *Col2a1*, were measured via counting the staining-positive cells in growth plates. These results are shown in Figure 5E.

> Figure 6D does not make sense. The text says 40% decrease in Fgf21 in 13del; CHOP-/- mice; however, the red line is above the green line in the figure?

Thank you for the comment. We have corrected this labelling mistake.

> The potential role of FGF21 in cell survival is interesting; however, given the long range signaling abilities of FGF21, it should be shown whether FGF21 is acting locally on HCs or indirectly through another factor and non HC tissue. Is beta-klotho expression changed in HCs and is FGFR1 responsible for supporting cell survival in 13del HCs? Given that Fgf21 was highly increased, could it have effects other that mediating the ISR? Does FGF21 regulate growth hormone signaling through STAT5, IGF-1, or IGF-1 binding protein (see PMC2575072, PMC3406689).
>
> Although probably beyond the scope of this study, it may be interesting to see how the 13del mouse responds to FGF21 treatment at the growth plate. Is there a direct effect on ERK phosphorylation?

Please see our response in Essential Revision \#1 above. Interestingly, HCs do not express beta-klotho and the expression level of STAT5, IGF-1 and IGF-1 binding protein was not changed in 13del HCs, examined by microarray (data not shown), suggesting that the pro-survival role of FGF21 in ER stressed HCs could be noncanonical. We have discussed these points in the revised manuscript (Discussion section).

> Figure 8B Blot is of low quality. The actin bands are not consistent. This could explain the differences seen between UHC and LHC. Quantification of this expression data would help especially for BIP.

Thank you for the comment. We have repeated the experiment, and better images were presented in new Figure 9B.

> Figure 9. It would be helpful to also indicate the suppressive effect of ISRIB on eIF2B and subsequently ATF4.

Thank you for the comment. We have added the mechanism of ISRIB action on eIF2B and subsequently on ATF4 in new Figure 10.

> Figure 9---figure supplement 1D. Label indicates that TUNEL is Red, however the probe is Green. Change for consistency.

Thank you for the comment. We have changed the label colour to green.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

> The manuscript has been improved and the response to reviewers is complete except for the statistical analysis. This is the only remaining issue prior to acceptance and we ask that the authors more fully justify the use of the Mann-U Whitney test, particularly as it relates to multiple comparisons in Figure 8 vs the more standard and accepted one way or in some cases two way ANOVA. We recommend that you consult a statistician for your response. Once this is resubmitted, we can rapidly make a final decision.

Thank you for the comment and advice. We have consulted a biostatistics expert. He pointed out that ANOVA (or t-test) is very robust to non-normality as long as the group sizes are close to being equal. He would only advise the use of Mann-Whitney when there is very gross violation of normality (e.g. clear outlying observations) and when the group sizes are grossly unequal. In our data the groups being compared are of similar size and there are no clear outliers. Thus, we expected ANOVA to be robust. Indeed, when we performed ANOVA on our ISRIB treatment data, we found that all the results are very similar to our previous results from Mann-Whitney. As ANOVA is the more commonly used procedure and has the advantage that it can be used to compare 3 or more groups in a single test, the expert considers it reasonable to present the ANOVA results only. Thus, following both the reviewer's suggestion and our expertise advice, we have presented the p-values obtained from ANOVA in Figure 8 and Figure 8---figure supplement 3.

[^1]: These authors contributed equally to this work.
